


What is claimed is:

1. A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

A, B, D, E, W, X, Y and Z are independently CR<sub>1</sub> or N;

T, U and V are independently CR<sub>8</sub> or N;

R<sub>1</sub> is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L<sub>a</sub>-R<sub>a</sub>;

R<sub>2</sub> is selected from nitro, cyano, -NHOH, and groups of the formula L<sub>a</sub>-R<sub>a</sub>; with the proviso that R<sub>2</sub> is not hydrogen;

R<sub>3</sub> and R<sub>4</sub> are:

- (a) each independently selected from (i) hydrogen and halogen; and (ii) C<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>2</sub>-C<sub>8</sub>alkyl ether and -(SO<sub>2</sub>)C<sub>1</sub>-C<sub>6</sub>alkyl, each of which is substituted with from 0 to 5 substituents independently chosen from halogen, hydroxy, amino, cyano and nitro; with the proviso that at least one of R<sub>3</sub> and R<sub>4</sub> is not hydrogen; or
- (b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings; and dioxane, wherein each fused ring is substituted with from 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, C<sub>1</sub>-C<sub>6</sub>alkyl and C<sub>1</sub>-C<sub>6</sub>haloalkyl;

R<sub>8</sub> is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkanoyl, C<sub>2</sub>-C<sub>6</sub>alkyl ether, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl)<sub>2</sub> and -N(C<sub>1</sub>-C<sub>6</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl;

L<sub>a</sub> is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, S(O)<sub>m</sub>, N(R<sub>x</sub>), N(R<sub>x</sub>)C(=O), N(R<sub>x</sub>)S(O)<sub>m</sub>, S(O)<sub>m</sub>N(R<sub>x</sub>) and N[S(O)<sub>m</sub>R<sub>x</sub>]S(O)<sub>m</sub>; wherein m is independently selected at each occurrence from 0, 1 and 2; and R<sub>x</sub> is independently selected at each occurrence from hydrogen and C<sub>1</sub>-C<sub>8</sub>alkyl; and

R<sub>a</sub> is independently selected at each occurrence from:

- (a) hydrogen; and
- (b) C<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>2</sub>-C<sub>8</sub>alkenyl, C<sub>2</sub>-C<sub>8</sub>alkynyl, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino(C<sub>0</sub>-C<sub>4</sub>alkyl), (5-membered heteroaryl)C<sub>0</sub>-C<sub>4</sub>alkyl and (5- to 7-membered heterocycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, aminocarbonyl, aminoC<sub>1</sub>-C<sub>6</sub>alkyl, and mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino.
2. A compound or pharmaceutically acceptable form thereof according to claim 1, wherein A is N.
3. A compound or pharmaceutically acceptable form thereof according to claim 1 or claim 2, wherein R<sub>2</sub> is selected from cyano, nitro, NHOH, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>haloalkyl, C<sub>1</sub>-C<sub>4</sub>hydroxyalkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>4</sub>alkylthio, C<sub>1</sub>-C<sub>4</sub>alkanoyl, aminoC<sub>0</sub>-C<sub>4</sub>alkyl, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino(C<sub>0</sub>-C<sub>4</sub>alkyl), (C<sub>5</sub>-C<sub>6</sub>cycloalkyl)amino, (5- or 6-membered heterocycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl, -N(R<sub>x</sub>)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl and -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl)<sub>2</sub>.
4. A compound or pharmaceutically acceptable form thereof according to claim 3, wherein R<sub>2</sub> is cyano, CHO, amino, nitro, methyl, ethyl, propyl, hydroxymethyl, trifluoromethyl, methoxy, ethoxy, propoxy, methylthio, ethylthio, (C<sub>1</sub>-C<sub>4</sub>alkyl)amino, (C<sub>1</sub>-C<sub>4</sub>alkyl)aminomethyl, cyclopentylamino, oxadiazolyl, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl, -N(CH<sub>3</sub>)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl or -N(SO<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>.
5. A compound or pharmaceutically acceptable form thereof according to claim 4, wherein R<sub>2</sub> is cyano, CHO, amino, nitro, methyl, trifluoromethyl, methoxy, ethoxy, propoxy, (C<sub>1</sub>-C<sub>4</sub>alkyl)amino, cyclopentylamino, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl, -N(CH<sub>3</sub>)SO<sub>2</sub>CH<sub>3</sub> or -N(SO<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>.
6. A compound or pharmaceutically acceptable form thereof according to any one of claims 1-5, wherein B and D are CR<sub>1</sub>, and wherein each R<sub>1</sub> at B and D is independently selected from hydrogen, halogen, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>haloalkyl and C<sub>1</sub>-C<sub>4</sub>alkoxy.
7. A compound or pharmaceutically acceptable form thereof according to any one of claims 1-6, wherein E is N or CR<sub>1</sub>, wherein R<sub>1</sub> at E is hydrogen, C<sub>1</sub>-C<sub>4</sub>alkyl or C<sub>1</sub>-C<sub>2</sub>alkoxy.
8. A compound or pharmaceutically acceptable form thereof according to any one of claims 1-7, wherein W, Y and Z are CR<sub>1</sub>, and wherein each R<sub>1</sub> at W, Y and Z is independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-

C<sub>4</sub>haloalkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl, -N(C<sub>1</sub>-C<sub>4</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl and -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl)<sub>2</sub>.

9. A compound or pharmaceutically acceptable form thereof according to claim 8, wherein X is N.


10. A compound or pharmaceutically acceptable form thereof according to claim 8, wherein each R<sub>1</sub> at W, Y and Z is independently chosen from hydrogen, halogen, hydroxy, amino, nitro and C<sub>1</sub>-C<sub>4</sub>alkyl.

11. A compound or pharmaceutically acceptable form thereof according to claim 8, wherein each R<sub>1</sub> at W, Y and Z is hydrogen.

12. A compound or pharmaceutically acceptable form thereof according to claim 10, wherein X is N or CH.

13. A compound or pharmaceutically acceptable form thereof according to any one of claims 1-12, wherein R<sub>3</sub> and R<sub>4</sub> are independently selected from hydrogen, halogen, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>2</sub>-C<sub>4</sub>alkyl ether, C<sub>1</sub>-C<sub>4</sub>haloalkyl, C<sub>1</sub>-C<sub>4</sub>hydroxyalkyl and -SO<sub>2</sub>CF<sub>3</sub>; or wherein R<sub>3</sub> and R<sub>4</sub> are taken together to form a fused ring chosen from 5-membered carbocyclic and heterocyclic rings, phenyl, dioxane and dioxepane.

14. A compound or pharmaceutically acceptable form thereof according to claim 1, having the formula:



15. A compound or pharmaceutically acceptable form thereof according to claim 14, wherein:

A, T, U and X are independently N or CH;

D is CH;

each R<sub>1</sub> is independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>haloalkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl, -N(C<sub>1</sub>-C<sub>4</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl and -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl)<sub>2</sub>;

R<sub>2</sub> is cyano, CHO, amino, nitro, methyl, ethyl, propyl, trifluoromethyl, methoxy, ethoxy, propoxy, methylthio, ethylthio, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl, -N(CH<sub>3</sub>)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl or -N(SO<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>; and

R<sub>3</sub> and R<sub>4</sub> are independently selected from hydrogen, halogen, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>2</sub>-C<sub>4</sub>alkyl ether, C<sub>1</sub>-C<sub>4</sub>haloalkyl, C<sub>1</sub>-C<sub>4</sub>hydroxyalkyl and -SO<sub>2</sub>CF<sub>3</sub>; or R<sub>3</sub> and R<sub>4</sub> are taken together to form a fused ring chosen from 5-membered carbocyclic and heterocyclic rings, phenyl, dioxane and dioxepane.

16. A compound or pharmaceutically acceptable form thereof according to claim 1, wherein the compound is:

- 2-Amino-N-(4-*tert*-butyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;
- 2-Amino-N-(4-trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;
- 2-Amino-N-(6-trifluoromethyl-pyridin-3-yl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;
- 2-Hydroxy-N-(4-trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;
- 2-Methanesulfonylamino-N-(4-trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;
- 2-Nitro-N-(4-trifluoromethanesulfonyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;
- 2-Nitro-N-(4-trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;
- 3-Hydroxy-2'-trifluoromethyl-biphenyl-4-carboxylic acid (4-*tert*-butyl-phenyl)-amide;
- 4-(3-Amino-pyridin-2-yl)-N-(4-*tert*-butyl-phenyl)-benzamide;
- 4-(3-Amino-pyridin-4-yl)-N-(4-*tert*-butyl-phenyl)-benzamide;
- 4-(3-Nitro-pyridin-2-yl)-N-(4-trifluoromethyl-phenyl)-benzamide;
- 4-[3-(Butane-1-sulfonylamino)-pyridin-2-yl]-N-(4-*tert*-butyl-phenyl)-benzamide;
- 6-(2,4-Dimethoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;
- 6-(2,4-Dimethoxy-phenyl)-N-(4-propyl-phenyl)-nicotinamide;
- 6-(2,4-Dimethoxy-phenyl)-N-(4-trifluoromethyl-phenyl)-nicotinamide;
- 6-(2,5-Dimethoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;
- 6-(2,5-Dimethoxy-phenyl)-N-(4-propyl-phenyl)-nicotinamide;
- 6-(2,5-Dimethyl-phenyl)-N-(3-fluoro-4-methyl-phenyl)-nicotinamide;
- 6-(2,5-Dimethyl-phenyl)-N-(4-ethyl-phenyl)-nicotinamide;
- 6-(2,5-Dimethyl-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;

6-(2,5-Dimethyl-phenyl)-N-(4-propyl-phenyl)-nicotinamide;  
 6-(2,5-Dimethyl-phenyl)-N-(4-trifluoromethyl-phenyl)-nicotinamide;  
 6-(2,5-Dimethyl-phenyl)-N-indan-5-yl-nicotinamide;  
 6-(2,6-Dimethoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;  
 6-(2,6-Dimethoxy-phenyl)-N-(4-trifluoromethyl-phenyl)-nicotinamide;  
 6-(2-Acetyl-phenyl)-N-(4-*tert*-butyl-phenyl)-nicotinamide;  
 6-(2-Amino-phenyl)-N-(4-*tert*-butyl-phenyl)-nicotinamide;  
 6-(2-Methoxy-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;  
 6-(2-Methoxy-phenyl)-N-(4-propyl-phenyl)-nicotinamide;  
 6-(2-Methoxy-phenyl)-N-(4-trifluoromethyl-phenyl)-nicotinamide;  
 6-(2-Methylsulfanyl-phenyl)-N-(4-propyl-phenyl)-nicotinamide;  
 6-(2-Methylsulfanyl-phenyl)-N-(4-trifluoromethyl-phenyl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-(3,4-dimethyl-phenyl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-(3-fluoro-4-methyl-phenyl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-(4-chloro-phenyl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-(4-ethyl-phenyl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-(4-propyl-phenyl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-(4-trifluoromethyl-phenyl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-indan-5-yl-nicotinamide;  
 6-(5-Fluoro-2-methoxy-phenyl)-N-(3-fluoro-4-methyl-phenyl)-nicotinamide;  
 6-(5-Fluoro-2-methoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;  
 6-(5-Fluoro-2-methoxy-phenyl)-N-(4-propyl-phenyl)-nicotinamide;  
 6-(5-Fluoro-2-methoxy-phenyl)-N-(4-trifluoromethyl-phenyl)-nicotinamide;  
 6-(5-Fluoro-2-methoxy-phenyl)-N-indan-5-yl-nicotinamide;  
 6-(5-Isopropyl-2-methoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;  
 6-Methyl-3'-trifluoromethyl-[2,2']bipyridinyl-5-carboxylic acid (4-trifluoromethyl-phenyl)-  
 amide;  
 6-o-Tolyl-N-(2,3,4-trifluoro-phenyl)-nicotinamide;  
 6-o-Tolyl-N-(3-trifluoromethyl-phenyl)-nicotinamide;  
 6-o-Tolyl-N-(4-trifluoromethyl-phenyl)-nicotinamide;  
 6-o-Tolyl-N-p-tolyl-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(2,5-dimethoxy-phenyl)-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(2,5-dimethyl-phenyl)-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(2-methoxy-phenyl)-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-o-tolyl-nicotinamide;  
 N-(3,4-Dichloro-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;  
 N-(3,4-Dichloro-phenyl)-6-o-tolyl-nicotinamide;  
 N-(3,4-Difluoro-phenyl)-6-o-tolyl-nicotinamide;  
 N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(2,5-dimethyl-phenyl)-nicotinamide;  
 N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(2-methoxy-phenyl)-nicotinamide;  
 N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;  
 N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(5-isopropyl-2-methoxy-phenyl)-  
 nicotinamide;  
 N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-o-tolyl-nicotinamide;  
 N-(3,4-Dimethyl-phenyl)-6-(2,5-dimethyl-phenyl)-nicotinamide;  
 N-(3,4-Dimethyl-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;  
 N-(3,4-Dimethyl-phenyl)-6-(2-methylsulfanyl-phenyl)-nicotinamide;  
 N-(3,4-Dimethyl-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;  
 N-(3,4-Dimethyl-phenyl)-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide;  
 N-(3,4-Dimethyl-phenyl)-6-o-tolyl-nicotinamide;  
 N-(3,5-Bis-trifluoromethyl-phenyl)-6-o-tolyl-nicotinamide;  
 N-(3,5-Dichloro-phenyl)-6-o-tolyl-nicotinamide;  
 N-(3-Chloro-phenyl)-6-o-tolyl-nicotinamide;  
 N-(3-Fluoro-4-methyl-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;  
 N-(3-Fluoro-4-methyl-phenyl)-6-(2-methylsulfanyl-phenyl)-nicotinamide;  
 N-(3-Fluoro-4-methyl-phenyl)-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide;  
 N-(3-Fluoro-4-methyl-phenyl)-6-o-tolyl-nicotinamide;  
 N-(3-Fluoro-phenyl)-6-o-tolyl-nicotinamide;  
 N-(3-*tert*-Butyl-phenyl)-6-(2,5-dimethyl-phenyl)-nicotinamide;  
 N-(3-*tert*-Butyl-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;  
 N-(3-*tert*-Butyl-phenyl)-6-(2-methylsulfanyl-phenyl)-nicotinamide;  
 N-(3-*tert*-Butyl-phenyl)-6-(5-chloro-2-methoxy-phenyl)-nicotinamide;  
 N-(3-*tert*-Butyl-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;


N-(4-Bromo-2-fluoro-phenyl)-6-o-tolyl-nicotinamide;  
 N-(4-Bromo-3-chloro-phenyl)-6-(2,4-dimethoxy-phenyl)-nicotinamide;  
 N-(4-Bromo-3-chloro-phenyl)-6-(2,5-dimethoxy-phenyl)-nicotinamide;  
 N-(4-Bromo-3-chloro-phenyl)-6-(2,5-dimethyl-phenyl)-nicotinamide;  
 N-(4-Bromo-3-chloro-phenyl)-6-(2,6-dimethoxy-phenyl)-nicotinamide;  
 N-(4-Bromo-3-chloro-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;  
 N-(4-Bromo-3-chloro-phenyl)-6-(2-methylsulfanyl-phenyl)-nicotinamide;  
 N-(4-Bromo-3-chloro-phenyl)-6-(5-chloro-2-methoxy-phenyl)-nicotinamide;  
 N-(4-Bromo-3-chloro-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;  
 N-(4-Bromo-3-chloro-phenyl)-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide;  
 N-(4-Bromo-3-chloro-phenyl)-6-o-tolyl-nicotinamide;  
 N-(4-Bromo-3-trifluoromethyl-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;  
 N-(4-Butyl-phenyl)-6-(2,4-dimethoxy-phenyl)-nicotinamide;  
 N-(4-Butyl-phenyl)-6-(2,5-dimethyl-phenyl)-nicotinamide;  
 N-(4-Butyl-phenyl)-6-(2,6-dimethoxy-phenyl)-nicotinamide;  
 N-(4-Butyl-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;  
 N-(4-Butyl-phenyl)-6-(2-methylsulfanyl-phenyl)-nicotinamide;  
 N-(4-Butyl-phenyl)-6-(5-chloro-2-methoxy-phenyl)-nicotinamide;  
 N-(4-Butyl-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;  
 N-(4-Butyl-phenyl)-6-o-tolyl-nicotinamide;  
 N-(4-Chloro-phenyl)-6-(2,4-dimethoxy-phenyl)-nicotinamide;  
 N-(4-Chloro-phenyl)-6-(2,5-dimethyl-phenyl)-nicotinamide;  
 N-(4-Chloro-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;  
 N-(4-Chloro-phenyl)-6-(2-methylsulfanyl-phenyl)-nicotinamide;  
 N-(4-Chloro-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;  
 N-(4-Chloro-phenyl)-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide;  
 N-(4-Chloro-phenyl)-6-o-tolyl-nicotinamide;  
 N-(4-Ethyl-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;  
 N-(4-Ethyl-phenyl)-6-(2-methylsulfanyl-phenyl)-nicotinamide;  
 N-(4-Ethyl-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;  
 N-(4-Ethyl-phenyl)-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide;  
 N-(4-Ethyl-phenyl)-6-o-tolyl-nicotinamide;  
 N-(4-Fluoro-phenyl)-6-o-tolyl-nicotinamide;  
 N-(4-Isopropyl-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;

N-(4-Isopropyl-phenyl)-6-(2-methylsulfanyl-phenyl)-nicotinamide;  
 N-(4-Isopropyl-phenyl)-6-o-tolyl-nicotinamide;  
 N-(4-Propyl-phenyl)-6-o-tolyl-nicotinamide;  
 N-(4-*tert*-Butyl-2-chloro-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;  
 N-(4-*tert*-Butyl-phenyl)-2-hydroxy-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-2-nitro-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-[1,3,4]oxadiazol-2-yl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-cyano-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-cyclopentylamino-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-dimethylaminomethyl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-ethanesulfonylamino-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-formyl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-hydroxyamino-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-hydroxymethyl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-methanesulfonylamino-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-methyl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-nitro-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-nitro-pyridin-4-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-propoxy-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-propylamino-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-pyrrolidin-1-ylmethyl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-[3-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyridin-2-yl]-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-[3-(methanesulfonyl-methyl-amino)-pyridin-2-yl]-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-[3-(N,N-dimethanesulfonyl)amino-pyridin-2-yl]-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-[3-(N,N-dimethanesulfonyl)amino-pyridin-4-yl]-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-6-(2,6-dimethyl-phenyl)-nicotinamide;  
 N-(4-*tert*-Butyl-phenyl)-6-(2-hydroxymethyl-phenyl)-nicotinamide;  
 N-(4-*tert*-Butyl-phenyl)-6-(2-methanesulfonylamino-phenyl)-nicotinamide;  
 N-(4-*tert*-Butyl-phenyl)-6-(2-nitro-phenyl)-nicotinamide;  
 N-(4-*tert*-Butyl-phenyl)-6-(2-trifluoromethyl-phenyl)-nicotinamide;  
 N-(4-*tert*-Butyl-phenyl)-6-[2-(N,N-dimethanesulfonyl)amino-phenyl]-nicotinamide;  
 N-(4-*tert*-Butyl-phenyl)-6-o-tolyl-nicotinamide;  
 N-(4-Trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;



N-(4-Trifluoromethyl-phenyl)-4-[3-(N,N-dimethanesulfonyl)amino-pyridin-2-yl]-benzamide;  
 N-(5-Trifluoromethyl-pyridin-2-yl)-4-[3-(N,N-dimethanesulfonyl)amino-pyridin-2-yl]-  
 benzamide;  
 N-Indan-5-yl-6-(2-methoxy-phenyl)-nicotinamide;  
 N-Indan-5-yl-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide; or  
 N-Indan-5-yl-6-o-tolyl-nicotinamide.

17. A compound of the formula:



wherein:

D, G, W, X, Y and Z are independently CR<sub>1</sub> or N;

T, U and V are independently CR<sub>8</sub> or N;

R<sub>1</sub> is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

R<sub>2</sub> is halogen, cyano, nitro or a group of the formula L-M; with the proviso that R<sub>2</sub> is not hydrogen;

R<sub>3</sub> and R<sub>4</sub> are:

(a) independently chosen from R<sub>8</sub>; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkanoyl, C<sub>2</sub>-C<sub>6</sub>alkyl ether, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino, C<sub>0</sub>-C<sub>4</sub>alkyl, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl)<sub>2</sub> and -N(C<sub>1</sub>-C<sub>6</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl;

R<sub>8</sub> is independently chosen at each occurrence from:

(a) hydrogen, halogen, hydroxy, amino, cyano and nitro; and

(b) C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkanoyl, C<sub>2</sub>-C<sub>6</sub>alkyl ether, -SO<sub>2</sub>CF<sub>3</sub>, 5- to 7-membered heterocycloalkyl, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl)<sub>2</sub> and -N(C<sub>1</sub>-C<sub>6</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl; each of

which is substituted with from 0 to 3 substituents independently selected from hydroxy, halogen, cyano, oxo, C<sub>1</sub>-C<sub>4</sub>alkyl and C<sub>1</sub>-C<sub>4</sub>haloalkyl;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, S(O)<sub>m</sub>, N(R<sub>x</sub>), C(=O)N(R<sub>x</sub>), N(R<sub>x</sub>)C(=O), N(R<sub>x</sub>)S(O)<sub>m</sub>, S(O)<sub>m</sub>N(R<sub>x</sub>) and N[S(O)<sub>m</sub>R<sub>x</sub>]S(O)<sub>m</sub>; wherein m is independently selected at each occurrence from 0, 1 and 2; and R<sub>x</sub> is independently selected at each occurrence from hydrogen and C<sub>1</sub>-C<sub>8</sub>alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b) C<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>2</sub>-C<sub>8</sub>alkenyl, C<sub>2</sub>-C<sub>8</sub>alkynyl, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino(C<sub>0</sub>-C<sub>4</sub>alkyl), phenylC<sub>0</sub>-C<sub>4</sub>alkyl, (5-membered heteroaryl)C<sub>0</sub>-C<sub>4</sub>alkyl and (5- to 7-membered heterocycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, aminocarbonyl, aminoC<sub>1</sub>-C<sub>6</sub>alkyl and mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino.

18. A compound or pharmaceutically acceptable form thereof according to claim 17, wherein R<sub>3</sub> is selected from:

- (a) halogen; and
- (b) C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkanoyl, -SO<sub>2</sub>CF<sub>3</sub>, C<sub>2</sub>-C<sub>6</sub>alkyl ether and 5- to 7-membered heterocycloalkyl, each of which is substituted with from 0 to 3 substituents independently selected from hydroxy, halogen, cyano, oxo, C<sub>1</sub>-C<sub>4</sub>alkyl and C<sub>1</sub>-C<sub>4</sub>haloalkyl.

19. A compound or pharmaceutically acceptable form thereof according to claim 18, wherein R<sub>3</sub> is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>hydroxyalkyl or C<sub>1</sub>-C<sub>6</sub>cyanoalkyl.

20. A compound or pharmaceutically acceptable form thereof according to any one of claims 17-19, wherein W, Y and Z are CR<sub>1</sub>, and wherein each R<sub>1</sub> at W, Y and Z is independently selected from hydrogen, halogen, hydroxy, amino, cyano, nitro, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>haloalkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl, -N(C<sub>1</sub>-C<sub>4</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl and -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl)<sub>2</sub>.

21. A compound or pharmaceutically acceptable form thereof according to claim 20, wherein X is N.

22. A compound or pharmaceutically acceptable form thereof according to claim 20, wherein each R<sub>1</sub> at W, Y and Z is independently chosen from hydrogen, halogen, amino, hydroxy, nitro, C<sub>1</sub>-C<sub>4</sub>alkyl and -NH(SO<sub>2</sub>)CH<sub>3</sub>.

23. A compound or pharmaceutically acceptable form thereof according to claim 21, wherein each R<sub>1</sub> at W, Y and Z is hydrogen.

24. A compound or pharmaceutically acceptable form thereof according to claim 23, wherein X is N or CH.

25. A compound or pharmaceutically acceptable form thereof according to any one of claims 17-24, wherein R<sub>2</sub> is selected from:

(i) halogen, nitro, cyano and -NOH; and

(ii) C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>alkylthio, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>hydroxyalkyl, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkanoyl, aminoC<sub>0</sub>-C<sub>6</sub>alkyl, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)aminoC<sub>0</sub>-C<sub>6</sub>alkyl, oxadiazolyl, pyrazolyl, (5- or 6-membered heterocycloalkyl)C<sub>0</sub>-C<sub>6</sub>alkyl, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, -N(C<sub>1</sub>-C<sub>6</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl)<sub>2</sub> and -N(H)SO<sub>2</sub>-(C<sub>0</sub>-C<sub>2</sub>alkyl)-phenyl; each of which is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl and C<sub>1</sub>-C<sub>4</sub>haloalkyl.

26. A compound or pharmaceutically acceptable form thereof according to claim 25, wherein R<sub>2</sub> is selected from fluoro, chloro, cyano, nitro, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>haloalkyl, C<sub>1</sub>-C<sub>4</sub>hydroxyalkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>4</sub>alkylthio, C<sub>1</sub>-C<sub>4</sub>alkanoyl, aminoC<sub>0</sub>-C<sub>4</sub>alkyl, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)aminoC<sub>0</sub>-C<sub>4</sub>alkyl, (C<sub>5</sub>-C<sub>6</sub>cycloalkyl)amino, (5- or 6-membered heterocycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl, -N(C<sub>1</sub>-C<sub>4</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl and -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl)<sub>2</sub>.

27. A compound or pharmaceutically acceptable form thereof according to claim 26, wherein R<sub>2</sub> is cyano, CHO, amino, nitro, NHOH, methyl, ethyl, propyl, trifluoromethyl, methoxy, ethoxy, propoxy, methylthio, ethylthio, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl, -N(H)SO<sub>2</sub>-phenyl, -N(CH<sub>3</sub>)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl or -N(SO<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>.

28. A compound or pharmaceutically acceptable form thereof according to claim 26, wherein R<sub>2</sub> is chloro, fluoro, cyano, nitro, amino, CHO, methyl, trifluoromethyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, cyclopentylamino, pyrrolidin-1-ylmethyl, hydroxymethyl, oxadiazolyl, C<sub>1</sub>-C<sub>4</sub>alkylamino, dimethylaminomethyl, -N(CH<sub>3</sub>)SO<sub>2</sub>CH<sub>3</sub> or -N(SO<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>.

29. A compound or pharmaceutically acceptable form thereof according to claim 17, wherein the compound is:


2-Amino-N-(4-*tert*-butyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

2-Amino-N-(4-trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

2-Amino-N-(6-trifluoromethyl-pyridin-3-yl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;  
 2-Hydroxy-N-(4-trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;  
 2-Methanesulfonylamino-N-(4-trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;  
 2-Nitro-N-(4-trifluoromethanesulfonyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;  
 2-Nitro-N-(4-trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;  
 2-Nitro-N-(6-trifluoromethyl-pyridin-3-yl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;  
 4-(3-Amino-pyridin-2-yl)-N-(4-*tert*-butyl-phenyl)-benzamide;  
 4-(3-Benzenesulfonylamino-pyridin-2-yl)-N-(4-*tert*-butyl-phenyl)-benzamide;  
 4-(3-Chloro-pyridin-2-yl)-N-(4-isopropyl-3-methyl-phenyl)-benzamide;  
 4-(3-Chloro-pyridin-2-yl)-N-(4-isopropyl-phenyl)-benzamide;  
 4-(3-Chloro-pyridin-2-yl)-N-(5-trifluoromethyl-pyridin-2-yl)-benzamide;  
 4-(3-Chloro-pyridin-2-yl)-N-[4-(1-hydroxy-1-methyl-ethyl)-phenyl]-benzamide;  
 4-(3-Chloro-pyridin-2-yl)-N-[4-(2,2,2-trifluoro-1-methyl-ethyl)-phenyl]-benzamide;  
 4-(3-Chloro-pyridin-2-yl)-N-[4-(2-methoxy-1,1-dimethyl-ethyl)-phenyl]-benzamide;  
 4-(3-Chloro-pyridin-2-yl)-N-[4-(cyano-dimethyl-methyl)-phenyl]-benzamide;  
 4-(3-Fluoro-pyridin-2-yl)-N-(4-isopropyl-3-methyl-phenyl)-benzamide;  
 4-(3-Fluoro-pyridin-2-yl)-N-(4-isopropyl-phenyl)-benzamide;  
 4-(3-Fluoro-pyridin-2-yl)-N-(4-trifluoromethyl-phenyl)-benzamide;  
 4-(3-Nitro-pyridin-2-yl)-N-(4-trifluoromethyl-phenyl)-benzamide;  
 4-[3-(Butane-1-sulfonylamino)-pyridin-2-yl]-N-(4-*tert*-butyl-phenyl)-benzamide;  
 6-Methyl-3'-trifluoromethyl-[2,2']bipyridinyl-5-carboxylic acid (4-trifluoromethyl-phenyl)-amide;  
 N-(3,4-Difluoro-phenyl)-4-(3-fluoro-pyridin-2-yl)-benzamide;  
 N-(4-Butyl-phenyl)-4-(3-chloro-pyridin-2-yl)-benzamide;  
 N-(4-Cyclopentyl-phenyl)-4-(3-fluoro-pyridin-2-yl)-benzamide;  
 N-(4-Fluoro-phenyl)-4-(3-fluoro-pyridin-2-yl)-benzamide;  
 N-(4-*sec*-Butyl-phenyl)-4-(3-fluoro-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-2-hydroxy-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-2-nitro-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3,5-dichloro-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-[1,3,4]oxadiazol-2-yl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-chloro-pyrazin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-chloro-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-cyano-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-cyclopentylamino-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-dimethylaminomethyl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-ethanesulfonylamino-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-fluoro-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-formyl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-hydroxyamino-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-hydroxymethyl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-methanesulfonylamino-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-methyl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-nitro-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-phenylmethanesulfonylamino-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-propoxy-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-propylamino-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-pyrrolidin-1-ylmethyl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-[3-(4-fluoro-benzenesulfonylamino)-pyridin-2-yl]-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-[3-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyridin-2-yl]-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-[3-(methanesulfonyl-methyl-amino)-pyridin-2-yl]-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-[3-(N,N-dimethanesulfonyl)amino-pyridin-2-yl]-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-[3-(toluene-4-sulfonylamino)-pyridin-2-yl]-benzamide;  
 N-(4-Trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;  
 N-(4-Trifluoromethyl-phenyl)-4-[3-(N,N-dimethanesulfonyl)amino-pyridin-2-yl]-benzamide;  
 N-(5-Trifluoromethyl-pyridin-2-yl)-4-[3-(N,N-dimethanesulfonyl)amino-pyridin-2-yl]-  
 benzamide; or  
 N-[4-(3-Ethyl-2,6-dioxo-piperidin-3-yl)-phenyl]-4-(3-fluoro-pyridin-2-yl)-benzamide.

30. A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

A, B, E, D and G are independently CH, CR<sub>7</sub> or N; with the proviso that at least one of G, D and E is CR<sub>7</sub>;

W, X, Y and Z are independently chosen from CR<sub>1</sub> and N;

T, U and V are independently chosen from CR<sub>8</sub> and N;

**R** represents a fused 5- or 7-membered carbocyclic or heterocyclic ring or a fused dioxane ring, wherein the fused ring is substituted with from 0 to 3 substituents independently selected from oxo, halogen, hydroxy, amino, cyano, nitro, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>haloalkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy and C<sub>1</sub>-C<sub>4</sub>haloalkoxy;

R<sub>1</sub> is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

R<sub>7</sub> is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M; with the proviso that R<sub>7</sub> is not hydrogen;

R<sub>8</sub> is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkanoyl, C<sub>2</sub>-C<sub>6</sub>alkyl ether, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl)<sub>2</sub> and -N(C<sub>1</sub>-C<sub>6</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, S(O)<sub>m</sub>, N(R<sub>x</sub>), C(=O)N(R<sub>x</sub>), N(R<sub>x</sub>)C(=O), N(R<sub>x</sub>)S(O)<sub>m</sub>, S(O)<sub>m</sub>N(R<sub>x</sub>) and N[S(O)<sub>m</sub>R<sub>x</sub>]S(O)<sub>m</sub>; wherein m is independently selected at each occurrence from 0, 1 and 2; and R<sub>x</sub> is independently selected at each occurrence from hydrogen and C<sub>1</sub>-C<sub>8</sub>alkyl; and

M is independently selected at each occurrence from:

(a) hydrogen, and

(b) C<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>2</sub>-C<sub>8</sub>alkenyl, C<sub>2</sub>-C<sub>8</sub>alkynyl, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino(C<sub>0</sub>-C<sub>4</sub>alkyl), phenylC<sub>0</sub>-C<sub>4</sub>alkyl, (5-membered heteroaryl)C<sub>0</sub>-C<sub>4</sub>alkyl and (5- to 7-membered heterocycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl, each of which is substituted with from 0 to 5 substituents

independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, aminocarbonyl, aminoC<sub>1</sub>-C<sub>6</sub>alkyl and mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino.

31. A compound or pharmaceutically acceptable form thereof according to claim 30, wherein at least two of W, X, Y and Z are CR<sub>1</sub>, and at least one of T and U is CR<sub>8</sub>.

32. A compound or pharmaceutically acceptable form thereof according to claim 30, wherein W, Y and Z are CR<sub>1</sub>, and wherein each R<sub>1</sub> is independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>haloalkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl, -N(C<sub>1</sub>-C<sub>4</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl and -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl)<sub>2</sub>.

33. A compound or pharmaceutically acceptable form thereof according to claim 32, wherein each R<sub>1</sub> is independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>haloalkyl and C<sub>1</sub>-C<sub>4</sub>alkoxy.

34. A compound or pharmaceutically acceptable form thereof according to claim 33, wherein each R<sub>1</sub> is hydrogen, and wherein X is N or CH.

35. A compound or pharmaceutically acceptable form thereof according to any one of claims 30-34, wherein X is N.

36. A compound or pharmaceutically acceptable form thereof according to any one of claims 30-35, wherein  $\textcircled{\text{R}}$  is selected from cyclopentene, thiazole, dioxolane, dioxane and dioxepane, each of which is substituted with from 0 to 2 substituents independently selected from oxo, halogen, hydroxy, amino, cyano, nitro, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>haloalkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, and C<sub>1</sub>-C<sub>4</sub>haloalkoxy.

37. A compound or pharmaceutically acceptable form thereof according to claim 36, wherein  $\textcircled{\text{R}}$  is cyclopentene, cyclopentene substituted with oxo, thiazole or methylthiazole.

38. A compound or pharmaceutically acceptable form thereof according to claim 36, wherein  $\textcircled{\text{R}}$  is dioxolane, dioxane or dioxepane.

39. A compound or pharmaceutically acceptable form thereof according to any one of claims 30-38, wherein G is CR<sub>7</sub>.

40. A compound or pharmaceutically acceptable form thereof according to claim 39, wherein B, D and E are CH or CR<sub>7</sub>.

41. A compound or pharmaceutically acceptable form thereof according to claim 39 or claim 40, wherein A is N or CH.

42. A compound or pharmaceutically acceptable form thereof according to claim 39, wherein R<sub>7</sub> at the G position is cyano, chloro, fluoro, nitro, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>haloalkyl, C<sub>1</sub>-C<sub>4</sub>hydroxyalkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>4</sub>alkylthio, C<sub>1</sub>-C<sub>4</sub>alkanoyl, aminoC<sub>0</sub>-C<sub>4</sub>alkyl, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino(C<sub>0</sub>-C<sub>4</sub>alkyl), (C<sub>5</sub>-C<sub>6</sub>cycloalkyl)amino, (5- or 6-membered heterocycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl, -N(H)SO<sub>2</sub>-(C<sub>0</sub>-C<sub>2</sub>alkyl)-phenyl, -N(C<sub>1</sub>-C<sub>4</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl or -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl)<sub>2</sub>.

43. A compound or pharmaceutically acceptable form thereof according to claim 30, wherein each R<sub>7</sub> is independently selected from halogen, amino, cyano, nitro, CHO, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>haloalkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>4</sub>alkylthio, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl, -N(CH<sub>3</sub>)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl and -N(SO<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>.

44. A compound or pharmaceutically acceptable form thereof according to claim 30, wherein the compound is:


- 6-(2,4-Difluoro-phenyl)-N-indan-5-yl-nicotinamide;
- 6-(2,5-Dimethyl-phenyl)-N-indan-5-yl-nicotinamide;
- 6-(2-Chloro-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;
- 6-(2-Fluoro-phenyl)-N-(1-oxo-indan-5-yl)-nicotinamide;
- 6-(2-Fluoro-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;
- 6-(2-Fluoro-phenyl)-N-indan-5-yl-nicotinamide;
- 6-(2-Methoxy-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;
- 6-(3,4-Difluoro-phenyl)-N-indan-5-yl-nicotinamide;
- 6-(3,4-Dimethyl-phenyl)-N-indan-5-yl-nicotinamide;
- 6-(3-Chloro-phenyl)-N-indan-5-yl-nicotinamide;
- 6-(3-Ethoxy-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;
- 6-(3-Ethoxy-phenyl)-N-indan-5-yl-nicotinamide;
- 6-(3-Fluoro-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;
- 6-(3-Fluoro-phenyl)-N-indan-5-yl-nicotinamide;
- 6-(3-Isopropyl-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;



6-(3-Methoxy-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;  
 6-(4-Butyl-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;  
 6-(4-Chloro-phenyl)-N-indan-5-yl-nicotinamide;  
 6-(4-Fluoro-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;  
 6-(4-Fluoro-phenyl)-N-indan-5-yl-nicotinamide;  
 6-(4-Isopropyl-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-indan-5-yl-nicotinamide;  
 6-(5-Fluoro-2-methoxy-phenyl)-N-indan-5-yl-nicotinamide;  
 6-Biphenyl-3-yl-N-indan-5-yl-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(2,5-dimethoxy-phenyl)-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(2,5-dimethyl-phenyl)-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(2-fluoro-phenyl)-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(2-methoxy-phenyl)-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(3-ethoxy-phenyl)-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(3-fluoro-phenyl)-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(3-isopropyl-phenyl)-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(3-methoxy-phenyl)-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(3-trifluoromethoxy-phenyl)-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(4-isopropyl-phenyl)-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-m-tolyl-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-o-tolyl-nicotinamide;  
 N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-p-tolyl-nicotinamide;  
 N-(2-Methyl-benzothiazol-5-yl)-6-(3-trifluoromethoxy-phenyl)-nicotinamide;  
 N-(2-Methyl-benzothiazol-5-yl)-6-m-tolyl-nicotinamide;  
 N-(2-Methyl-benzothiazol-5-yl)-6-p-tolyl-nicotinamide;  
 N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(2,5-dimethyl-phenyl)-nicotinamide;  
 N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(2-fluoro-phenyl)-nicotinamide;  
 N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(2-methoxy-phenyl)-nicotinamide;  
 N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(3-fluoro-phenyl)-nicotinamide;  
 N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(3-isopropyl-phenyl)-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(3-methoxy-phenyl)-nicotinamide;  
 N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(3-trifluoromethoxy-phenyl)-nicotinamide;  
 N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(4-fluoro-phenyl)-nicotinamide;  
 N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(4-isopropyl-phenyl)-nicotinamide;  
 N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;  
 N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(5-isopropyl-2-methoxy-phenyl)-  
 nicotinamide;  
 N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-m-tolyl-nicotinamide;  
 N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-o-tolyl-nicotinamide;  
 N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-p-tolyl-nicotinamide;  
 N-Indan-5-yl-6-(2-methoxy-phenyl)-nicotinamide;  
 N-Indan-5-yl-6-(3,4,5-trimethoxy-phenyl)-nicotinamide;  
 N-Indan-5-yl-6-(3-isopropyl-phenyl)-nicotinamide;  
 N-Indan-5-yl-6-(3-methoxy-phenyl)-nicotinamide;  
 N-Indan-5-yl-6-(3-trifluoromethoxy-phenyl)-nicotinamide;  
 N-Indan-5-yl-6-(3-trifluoromethyl-phenyl)-nicotinamide;  
 N-Indan-5-yl-6-(4-isopropyl-phenyl)-nicotinamide;  
 N-Indan-5-yl-6-(4-methoxy-phenyl)-nicotinamide;  
 N-Indan-5-yl-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide;  
 N-Indan-5-yl-6-m-tolyl-nicotinamide;  
 N-Indan-5-yl-6-o-tolyl-nicotinamide; or  
 N-Indan-5-yl-6-p-tolyl-nicotinamide.

45. A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

J is N, NH, O or S;

A, B, E, D and G are independently CH, CR<sub>7</sub> or N; with the proviso that at least one of G, D and E is CR<sub>7</sub>;

W, X, Y and Z are independently CR<sub>1</sub> or N;

T, U and V are independently CR<sub>8</sub> or N;

R<sub>1</sub> is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-R<sub>a</sub>;

R<sub>7</sub> is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-R<sub>a</sub>, with the proviso that R<sub>7</sub> is not hydrogen;

R<sub>8</sub> is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkanoyl, C<sub>2</sub>-C<sub>6</sub>alkyl ether, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl)<sub>2</sub> and -N(C<sub>1</sub>-C<sub>6</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl;

R<sub>9</sub> represents from 0 to 2 substituents independently chosen from halogen, cyano, nitro, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>4</sub>haloalkyl, C<sub>1</sub>-C<sub>4</sub>haloalkoxy, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino, and C<sub>2</sub>-C<sub>6</sub>alkyl ether;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, S(O)<sub>m</sub>, N(R<sub>x</sub>), C(=O)N(R<sub>x</sub>), N(R<sub>x</sub>)C(=O), N(R<sub>x</sub>)S(O)<sub>m</sub>, S(O)<sub>m</sub>N(R<sub>x</sub>) and N[S(O)<sub>m</sub>R<sub>x</sub>]S(O)<sub>m</sub>; wherein m is independently selected at each occurrence from 0, 1 and 2; and R<sub>x</sub> is independently selected at each occurrence from hydrogen and C<sub>1</sub>-C<sub>8</sub>alkyl; and

R<sub>a</sub> is independently selected at each occurrence from:

(a) hydrogen; and

(b) C<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>2</sub>-C<sub>8</sub>alkenyl, C<sub>2</sub>-C<sub>8</sub>alkynyl, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino(C<sub>0</sub>-C<sub>4</sub>alkyl), and (5- to 7-membered heterocycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, aminocarbonyl, aminoC<sub>1</sub>-C<sub>6</sub>alkyl and mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino.

46. A compound or pharmaceutically acceptable form thereof according to claim 45, wherein at least two of W, X, Y and Z are CR<sub>1</sub>, at least one of T and U is CR<sub>8</sub>, and each R<sub>1</sub> and R<sub>8</sub> is independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>haloalkyl and C<sub>1</sub>-C<sub>4</sub>alkoxy.

47. A compound or pharmaceutically acceptable form thereof according to claim 46, wherein W, Y and Z are CR<sub>1</sub>, and wherein each R<sub>1</sub> is independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>haloalkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl, -N(C<sub>1</sub>-C<sub>4</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl and -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl)<sub>2</sub>.

48. A compound or pharmaceutically acceptable form thereof according to claim 47, wherein each R<sub>1</sub> is independently chosen from hydrogen, halogen, hydroxy and C<sub>1</sub>-C<sub>4</sub>alkyl.

49. A compound or pharmaceutically acceptable form thereof according to claim 48, wherein R<sub>1</sub> at W, Y and Z is hydrogen, and wherein X is N or CH.

50. A compound or pharmaceutically acceptable form thereof according to claim 46, wherein X is N.

51. A compound or pharmaceutically acceptable form thereof according to claim 45, wherein A is N or CH.

52. A compound or pharmaceutically acceptable form thereof according to claim 45, wherein G is CR<sub>7</sub>.

53. A compound or pharmaceutically acceptable form thereof according to claim 52, wherein R<sub>7</sub> at the G position is cyano, chloro, fluoro, nitro, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>haloalkyl, C<sub>1</sub>-C<sub>4</sub>hydroxyalkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>4</sub>alkylthio, C<sub>1</sub>-C<sub>4</sub>alkanoyl, aminoC<sub>0</sub>-C<sub>4</sub>alkyl, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino(C<sub>0</sub>-C<sub>4</sub>alkyl), (C<sub>5</sub>-C<sub>6</sub>cycloalkyl)amino, (5- or 6-membered heterocycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl, -N(C<sub>1</sub>-C<sub>4</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl or -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl)<sub>2</sub>.

54. A compound or pharmaceutically acceptable form thereof according to claim 45, wherein each R<sub>7</sub> is independently selected from halogen, amino, cyano, nitro, CHO, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>haloalkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>4</sub>alkylthio, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl, -N(CH<sub>3</sub>)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl and -N(SO<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>.

55. A compound or pharmaceutically acceptable form thereof according to claim 45, wherein J is O.


56. A compound or pharmaceutically acceptable form thereof according to claim 45, wherein R<sub>9</sub> represents from 0 to 2 substituents independently chosen from halogen, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>4</sub>haloalkyl and C<sub>1</sub>-C<sub>4</sub>haloalkoxy.

57. A compound or pharmaceutically acceptable form thereof according to claim 45, wherein R<sub>9</sub> represents 0 substituents.

58. A compounds or form thereof according to claim 45, wherein:  
J is O;  
each R<sub>7</sub> is independently selected from halogen, amino, cyano, nitro, CHO, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>haloalkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>4</sub>alkylthio, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl, -N(CH<sub>3</sub>)SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub>alkyl and -N(SO<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>;  
R<sub>1</sub> at W, Y and Z is CR<sub>1</sub>, wherein each R<sub>1</sub> is independently chosen from hydrogen, halogen, hydroxy and C<sub>1</sub>-C<sub>4</sub>alkyl;  
A is N or CH; and  
T and U are independently N or CH.

59. A compound or pharmaceutically acceptable form thereof according to claim 45, wherein the compound is:  
6-(2,5-Dimethyl-phenyl)-N-(4-morpholin-4-yl-phenyl)-nicotinamide;  
6-(2-Chloro-phenyl)-N-(4-morpholin-4-yl-phenyl)-nicotinamide;  
6-(2-Fluoro-phenyl)-N-(4-morpholin-4-yl-phenyl)-nicotinamide;  
6-(2-Methoxy-phenyl)-N-(4-morpholin-4-yl-phenyl)-nicotinamide;  
6-(3,4-Dimethyl-phenyl)-N-(4-morpholin-4-yl-phenyl)-nicotinamide;  
6-(3,5-Dimethyl-phenyl)-N-(4-morpholin-4-yl-phenyl)-nicotinamide;  
6-(3-Isopropyl-phenyl)-N-(4-morpholin-4-yl-phenyl)-nicotinamide;  
6-(4-Isopropyl-phenyl)-N-(4-morpholin-4-yl-phenyl)-nicotinamide;  
6-(5-Isopropyl-2-methoxy-phenyl)-N-(4-morpholin-4-yl-phenyl)-nicotinamide;  
N-(3-Chloro-4-morpholin-4-yl-phenyl)-6-(2-chloro-phenyl)-nicotinamide;  
N-(3-Chloro-4-morpholin-4-yl-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;  
N-(3-Chloro-4-morpholin-4-yl-phenyl)-6-o-tolyl-nicotinamide;  
N-(4-Morpholin-4-yl-phenyl)-6-m-tolyl-nicotinamide; or  
N-(4-Morpholin-4-yl-phenyl)-6-o-tolyl-nicotinamide.

60. A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

A, T, W, X, Y, Z are independently CR<sub>1</sub> or N;

each R<sub>1</sub> and R<sub>8</sub> is independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>4</sub>haloalkyl and C<sub>1</sub>-C<sub>4</sub>haloalkoxy;

either:

(a) R<sub>2</sub> is a halogen and R<sub>5</sub> is hydrogen; or

(b) R<sub>2</sub> is hydrogen and R<sub>5</sub> is a halogen; and

with regard to R<sub>3</sub> and R<sub>4</sub>:

(a) R<sub>3</sub> is C<sub>1</sub>-C<sub>6</sub>alkyl and R<sub>4</sub> is hydrogen, halogen, hydroxy, amino, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>4</sub>haloalkyl or C<sub>1</sub>-C<sub>4</sub>haloalkoxy;

(b) R<sub>3</sub> is hydrogen, halogen, amino, cyano or C<sub>1</sub>-C<sub>4</sub>alkoxy; and R<sub>4</sub> is halogen, hydroxy, amino, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl or C<sub>1</sub>-C<sub>4</sub>alkoxy; or

(c) R<sub>3</sub> and R<sub>4</sub> are taken together to form a 5- or 6-membered partially saturated carbocycle substituted with from 0 to 2 substituents independently chosen from halogen, hydroxy, amino, cyano, nitro, oxo, C<sub>1</sub>-C<sub>4</sub>alkyl and C<sub>1</sub>-C<sub>4</sub>alkoxy.

61. A compound or pharmaceutically acceptable form thereof according to claim 60, wherein:

W and X are CH;

A and T are independently CH or N;

Each R<sub>8</sub> is hydrogen; and

each R<sub>1</sub> is hydrogen or halogen.

62. A compound of form thereof according to claim 61, wherein R<sub>3</sub> is C<sub>1</sub>-C<sub>6</sub>alkyl and R<sub>4</sub> is hydrogen, methyl or halogen.

63. A compound or pharmaceutically acceptable form thereof according to claim 61, wherein R<sub>3</sub> is hydrogen or halogen and R<sub>4</sub> is halogen.

64. A compound or pharmaceutically acceptable form thereof according to claim 60, wherein the compound is:


2'-Chloro-biphenyl-4-carboxylic acid (4-*tert*-butyl-phenyl)-amide;  
4-(3-Chloro-pyridin-2-yl)-N-(4-isopropyl-3-methyl-phenyl)-benzamide;  
4-(3-Chloro-pyridin-2-yl)-N-(4-isopropyl-phenyl)-benzamide;  
4-(3-Fluoro-pyridin-2-yl)-N-(4-isopropyl-3-methyl-phenyl)-benzamide;  
4-(3-Fluoro-pyridin-2-yl)-N-(4-isopropyl-phenyl)-benzamide;  
5-(2-Chloro-phenyl)-pyrazine-2-carboxylic acid (4-*sec*-butyl-phenyl)-amide;  
5-(2-Chloro-phenyl)-pyrazine-2-carboxylic acid (4-*tert*-butyl-phenyl)-amide;  
5-(2-Chloro-phenyl)-pyridine-2-carboxylic acid (4-*tert*-butyl-phenyl)-amide;  
6-(2,4-Difluoro-phenyl)-N-(3,4-dimethyl-phenyl)-nicotinamide;  
6-(2,4-Difluoro-phenyl)-N-indan-5-yl-nicotinamide;  
6-(2-Chloro-phenyl)-N-(2,3,4-trifluoro-phenyl)-nicotinamide;  
6-(2-Chloro-phenyl)-N-(3,4-dichloro-phenyl)-nicotinamide;  
6-(2-Chloro-phenyl)-N-(3,4-difluoro-phenyl)-nicotinamide;  
6-(2-Chloro-phenyl)-N-(3,5-dichloro-phenyl)-nicotinamide;  
6-(2-Chloro-phenyl)-N-(3-fluoro-4-methyl-phenyl)-nicotinamide;  
6-(2-Chloro-phenyl)-N-(3-fluoro-phenyl)-nicotinamide;  
6-(2-Chloro-phenyl)-N-(3-methoxy-phenyl)-nicotinamide;  
6-(2-Chloro-phenyl)-N-(4-ethyl-phenyl)-nicotinamide;  
6-(2-Chloro-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;  
6-(2-Chloro-phenyl)-N-(4-propyl-phenyl)-nicotinamide;  
6-(2-Chloro-phenyl)-N-*m*-tolyl-nicotinamide;  
6-(2-Fluoro-phenyl)-N-(1-oxo-indan-5-yl)-nicotinamide;  
6-(2-Fluoro-phenyl)-N-(3-methoxy-phenyl)-nicotinamide;  
6-(2-Fluoro-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;  
6-(2-Fluoro-phenyl)-N-(4-propyl-phenyl)-nicotinamide;  
6-(2-Fluoro-phenyl)-N-indan-5-yl-nicotinamide;  
6-(2-Fluoro-phenyl)-N-*m*-tolyl-nicotinamide;  
6-(3,4-Difluoro-phenyl)-N-(3,4-dimethyl-phenyl)-nicotinamide;  
6-(3,4-Difluoro-phenyl)-N-(3-fluoro-4-methyl-phenyl)-nicotinamide;

6-(3,4-Difluoro-phenyl)-N-indan-5-yl-nicotinamide;  
 6-(3-Chloro-phenyl)-N-(3,4-dimethyl-phenyl)-nicotinamide;  
 6-(3-Chloro-phenyl)-N-(3-fluoro-4-methyl-phenyl)-nicotinamide;  
 6-(3-Chloro-phenyl)-N-(4-ethyl-phenyl)-nicotinamide;  
 6-(3-Chloro-phenyl)-N-indan-5-yl-nicotinamide;  
 6-(3-Fluoro-phenyl)-N-(3-methoxy-phenyl)-nicotinamide;  
 6-(3-Fluoro-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;  
 6-(3-Fluoro-phenyl)-N-(4-propyl-phenyl)-nicotinamide;  
 6-(3-Fluoro-phenyl)-N-indan-5-yl-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-(3,4-dimethyl-phenyl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-(3-fluoro-4-methyl-phenyl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-(3-methoxy-phenyl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-(4-ethyl-phenyl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-(4-propyl-phenyl)-nicotinamide;  
 6-(5-Chloro-2-methoxy-phenyl)-N-indan-5-yl-nicotinamide;  
 6-(5-Fluoro-2-methoxy-phenyl)-N-(3-fluoro-4-methyl-phenyl)-nicotinamide;  
 6-(5-Fluoro-2-methoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;  
 6-(5-Fluoro-2-methoxy-phenyl)-N-(4-propyl-phenyl)-nicotinamide;  
 6-(5-Fluoro-2-methoxy-phenyl)-N-indan-5-yl-nicotinamide;  
 N-(3,4-Dichloro-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;  
 N-(3,4-Difluoro-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;  
 N-(3,4-Dimethoxy-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;  
 N-(3,4-Dimethyl-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;  
 N-(3,4-Dimethyl-phenyl)-6-(3-fluoro-phenyl)-nicotinamide;  
 N-(3,4-Dimethyl-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;  
 N-(3,5-Dichloro-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;  
 N-(3-Chloro-phenyl)-6-(2-chloro-phenyl)-nicotinamide;  
 N-(3-Chloro-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;  
 N-(3-Fluoro-4-methyl-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;  
 N-(3-Fluoro-4-methyl-phenyl)-6-(3-fluoro-phenyl)-nicotinamide;  
 N-(3-Fluoro-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;  
 N-(3-*tert*-Butyl-phenyl)-6-(2,4-difluoro-phenyl)-nicotinamide;  
 N-(3-*tert*-Butyl-phenyl)-6-(2-chloro-phenyl)-nicotinamide;



N-(3-*tert*-Butyl-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;  
 N-(3-*tert*-Butyl-phenyl)-6-(3,4-difluoro-phenyl)-nicotinamide;  
 N-(3-*tert*-Butyl-phenyl)-6-(3-chloro-phenyl)-nicotinamide;  
 N-(3-*tert*-Butyl-phenyl)-6-(3-fluoro-phenyl)-nicotinamide;  
 N-(3-*tert*-Butyl-phenyl)-6-(5-chloro-2-methoxy-phenyl)-nicotinamide;  
 N-(3-*tert*-Butyl-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;  
 N-(4-Bromo-3-chloro-phenyl)-6-(2-chloro-phenyl)-nicotinamide;  
 N-(4-Bromo-3-chloro-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;  
 N-(4-Bromo-3-chloro-phenyl)-6-(3-fluoro-phenyl)-nicotinamide;  
 N-(4-Butyl-phenyl)-4-(3-chloro-pyridin-2-yl)-benzamide;  
 N-(4-Butyl-phenyl)-6-(2-chloro-phenyl)-nicotinamide;  
 N-(4-Butyl-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;  
 N-(4-Butyl-phenyl)-6-(5-chloro-2-methoxy-phenyl)-nicotinamide;  
 N-(4-Butyl-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;  
 N-(4-Ethyl-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;  
 N-(4-Ethyl-phenyl)-6-(3-fluoro-phenyl)-nicotinamide;  
 N-(4-Ethyl-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;  
 N-(4-*sec*-Butyl-phenyl)-4-(3-fluoro-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-2-chloro-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3,5-dichloro-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-chloro-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-4-(3-fluoro-pyridin-2-yl)-benzamide;  
 N-(4-*tert*-Butyl-phenyl)-5-chloro-6-(2-chloro-phenyl)-nicotinamide;  
 N-(4-*tert*-Butyl-phenyl)-6-(2,4-difluoro-phenyl)-nicotinamide;  
 N-(4-*tert*-Butyl-phenyl)-6-(2,6-difluoro-phenyl)-nicotinamide;  
 N-(4-*tert*-Butyl-phenyl)-6-(2-chloro-4-ethoxy-phenyl)-nicotinamide;  
 N-(4-*tert*-Butyl-phenyl)-6-(2-chloro-phenyl)-4-hydroxy-nicotinamide;  
 N-(4-*tert*-Butyl-phenyl)-6-(2-chloro-phenyl)-nicotinamide;  
 N-(4-*tert*-Butyl-phenyl)-6-(2-fluoro-phenyl)-nicotinamide; or  
 N-(4-*tert*-Butyl-phenyl)-6-(3-fluoro-phenyl)-nicotinamide.

65. A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

A and T are independently CH or N;

W, X, Y and Z are independently CR<sub>1</sub> or N;

R<sub>1</sub> and R<sub>8</sub> are independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>4</sub>haloalkyl and C<sub>1</sub>-C<sub>4</sub>haloalkoxy;

R<sub>3</sub> and R<sub>4</sub> are:

- (a) independently chosen from hydrogen, halogen, hydroxy, amino, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>4</sub>haloalkyl and C<sub>1</sub>-C<sub>4</sub>haloalkoxy; or
- (b) taken together to form a fused ring chosen from 5- to 7-membered partially saturated carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, wherein the fused ring is substituted with from 0 to 2 substituents independently chosen from halogen, hydroxy, amino, cyano, nitro, oxo, C<sub>1</sub>-C<sub>4</sub>alkyl, and C<sub>1</sub>-C<sub>4</sub>alkoxy;

R<sub>5</sub> is:

- (a) C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkenyl or C<sub>1</sub>-C<sub>6</sub>alkynyl; or
  - (b) taken together with R<sub>6</sub> to form a fused 5- to 7-membered partially saturated heterocycle;
- and

R<sub>6</sub> is:

- (a) hydrogen, halogen, hydroxy, amino, cyano, nitro, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>4</sub>haloalkyl or C<sub>1</sub>-C<sub>4</sub>haloalkoxy; or
- (b) taken together with R<sub>5</sub> to form a fused 5- to 7-membered partially saturated heterocycle.

66. A compound or pharmaceutically acceptable form thereof according to claim 65, wherein R<sub>3</sub> and R<sub>4</sub> are taken together to form a fused cyclopentene, thiazole, dioxolane or dioxane ring, each of which is unsubstituted or substituted with a methyl group.

67. A compound or pharmaceutically acceptable form thereof according to claim 65, wherein R<sub>3</sub> is C<sub>1</sub>-C<sub>6</sub>alkyl or halogen and R<sub>4</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl or halogen.


68. A compound or pharmaceutically acceptable form thereof according to claim 65, wherein each R<sub>1</sub> and R<sub>8</sub> is hydrogen.

69. A compound or pharmaceutically acceptable form thereof according to claim 65, wherein the compound is:

6-(3,4-Dimethoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;  
6-(3-Ethoxy-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;  
6-(3-Ethoxy-phenyl)-N-(3-fluoro-4-methyl-phenyl)-nicotinamide;  
6-(3-Ethoxy-phenyl)-N-(3-methoxy-phenyl)-nicotinamide;  
6-(3-Ethoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;  
6-(3-Ethoxy-phenyl)-N-(4-trifluoromethyl-phenyl)-nicotinamide;  
6-(3-Ethoxy-phenyl)-N-indan-5-yl-nicotinamide;  
6-(3-Methoxy-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;  
6-(3-Methoxy-phenyl)-N-(4-propyl-phenyl)-nicotinamide;  
6-(3-Trifluoromethoxy-phenyl)-N-(4-trifluoromethyl-phenyl)-nicotinamide;  
6-Benzo[1,3]dioxol-5-yl-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;  
6-Benzo[1,3]dioxol-5-yl-N-(3,4-dimethyl-phenyl)-nicotinamide;  
6-Benzo[1,3]dioxol-5-yl-N-(3-methoxy-phenyl)-nicotinamide;  
6-Benzo[1,3]dioxol-5-yl-N-(3-*tert*-butyl-phenyl)-nicotinamide;  
6-Benzo[1,3]dioxol-5-yl-N-(4-isopropyl-phenyl)-nicotinamide;  
N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(3-ethoxy-phenyl)-nicotinamide;  
N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(3-methoxy-phenyl)-nicotinamide;  
N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(3-trifluoromethoxy-phenyl)-nicotinamide;  
N-(2-Methyl-benzothiazol-5-yl)-6-(3-trifluoromethoxy-phenyl)-nicotinamide;  
N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(3-methoxy-phenyl)-nicotinamide;  
N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(3-trifluoromethoxy-phenyl)-nicotinamide;  
N-(3,4-Dimethyl-phenyl)-6-(3-ethoxy-phenyl)-nicotinamide;  
N-(3,4-Dimethyl-phenyl)-6-(3-methoxy-phenyl)-nicotinamide;  
N-(3,4-Dimethyl-phenyl)-6-(3-trifluoromethoxy-phenyl)-nicotinamide;  
N-(3-Fluoro-4-methyl-phenyl)-6-(3-methoxy-phenyl)-nicotinamide;  
N-(3-Methoxy-phenyl)-6-(3,4,5-trimethoxy-phenyl)-nicotinamide;

N-(3-Methoxy-phenyl)-6-(3-trifluoromethoxy-phenyl)-nicotinamide;  
 N-(3-*tert*-Butyl-phenyl)-6-(3,4,5-trimethoxy-phenyl)-nicotinamide;  
 N-(3-*tert*-Butyl-phenyl)-6-(3-methoxy-phenyl)-nicotinamide;  
 N-(3-*tert*-Butyl-phenyl)-6-(4-trifluoromethoxy-phenyl)-nicotinamide;  
 N-(4-Bromo-3-chloro-phenyl)-6-(3,4,5-trimethoxy-phenyl)-nicotinamide;  
 N-(4-Bromo-3-chloro-phenyl)-6-(3,4-dimethoxy-phenyl)-nicotinamide;  
 N-(4-Bromo-3-chloro-phenyl)-6-(3-ethoxy-phenyl)-nicotinamide;  
 N-(4-Bromo-3-chloro-phenyl)-6-(3-methoxy-phenyl)-nicotinamide;  
 N-(4-Butyl-phenyl)-6-(3-methoxy-phenyl)-nicotinamide;  
 N-(4-Chloro-phenyl)-6-(3-ethoxy-phenyl)-nicotinamide;  
 N-(4-Chloro-phenyl)-6-(3-methoxy-phenyl)-nicotinamide;  
 N-(4-Ethyl-phenyl)-6-(3,4,5-trimethoxy-phenyl)-nicotinamide;  
 N-(4-Ethyl-phenyl)-6-(3-methoxy-phenyl)-nicotinamide;  
 N-(4-Isopropyl-phenyl)-6-(3,4,5-trimethoxy-phenyl)-nicotinamide;  
 N-(4-Isopropyl-phenyl)-6-(3-trifluoromethoxy-phenyl)-nicotinamide;  
 N-(4-*tert*-Butyl-phenyl)-6-(3-methoxy-phenyl)-nicotinamide;  
 N-Indan-5-yl-6-(3,4,5-trimethoxy-phenyl)-nicotinamide;  
 N-Indan-5-yl-6-(3-methoxy-phenyl)-nicotinamide; or  
 N-Indan-5-yl-6-(3-trifluoromethoxy-phenyl)-nicotinamide.

70. A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

T, U, V, W, X, Y and Z are independently CR<sub>1</sub> or N;

R<sub>1</sub> is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

R<sub>3</sub> and R<sub>4</sub> are:

(a) independently chosen from R<sub>1</sub>; or


(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkanoyl, C<sub>2</sub>-C<sub>6</sub>alkyl ether, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino, C<sub>0</sub>-C<sub>4</sub>alkyl, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl)<sub>2</sub> and -N(C<sub>1</sub>-C<sub>6</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl;

R<sub>20</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkanoyl or -SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, S(O)<sub>m</sub>, N(R<sub>x</sub>), C(=O)N(R<sub>x</sub>), N(R<sub>x</sub>)C(=O), N(R<sub>x</sub>)S(O)<sub>m</sub>, S(O)<sub>m</sub>N(R<sub>x</sub>) and N[S(O)<sub>m</sub>R<sub>x</sub>]S(O)<sub>m</sub>; wherein m is independently selected at each occurrence from 0, 1 and 2; and R<sub>x</sub> is independently selected at each occurrence from hydrogen and C<sub>1</sub>-C<sub>8</sub>alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b) C<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>2</sub>-C<sub>8</sub>alkenyl, C<sub>2</sub>-C<sub>8</sub>alkynyl, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino(C<sub>0</sub>-C<sub>4</sub>alkyl), phenylC<sub>0</sub>-C<sub>4</sub>alkyl and (5- to 7-membered heterocycle)C<sub>0</sub>-C<sub>4</sub>alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, aminocarbonyl, aminoC<sub>1</sub>-C<sub>6</sub>alkyl and mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino.

71. A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

A, B, E, D, G, W, X, Y and Z are independently CR<sub>1</sub> or N;

R<sub>3</sub> and R<sub>4</sub> are independently chosen from R<sub>1</sub>;

R<sub>1</sub> is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, S(O)<sub>m</sub>, N(R<sub>x</sub>), C(=O)N(R<sub>x</sub>), N(R<sub>x</sub>)C(=O), N(R<sub>x</sub>)S(O)<sub>m</sub>, S(O)<sub>m</sub>N(R<sub>x</sub>) and N[S(O)<sub>m</sub>R<sub>x</sub>]S(O)<sub>m</sub>; wherein m is independently selected at each occurrence from 0, 1 and 2; and R<sub>x</sub> is independently selected at each occurrence from hydrogen and C<sub>1</sub>-C<sub>8</sub>alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b) C<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>2</sub>-C<sub>8</sub>alkenyl, C<sub>2</sub>-C<sub>8</sub>alkynyl, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino(C<sub>0</sub>-C<sub>4</sub>alkyl), phenylC<sub>0</sub>-C<sub>4</sub>alkyl and (5- to 7-membered heterocycle)C<sub>0</sub>-C<sub>4</sub>alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, aminocarbonyl, aminoC<sub>1</sub>-C<sub>6</sub>alkyl and mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino.

72. A compound or pharmaceutically acceptable form thereof according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71, wherein the compound has an IC<sub>50</sub> value of 100 nanomolar or less in a capsaicin receptor calcium mobilization assay.


73. A compound or pharmaceutically acceptable form thereof according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71, wherein the compound has an IC<sub>50</sub> value of 10 nanomolar or less in a capsaicin receptor calcium mobilization assay.

74. A compound or pharmaceutically acceptable form thereof according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71, wherein the compound has an IC<sub>50</sub> value of 1 nanomolar or less in a capsaicin receptor calcium mobilization assay.

75. A pharmaceutical composition, comprising at least one compound or pharmaceutically acceptable form thereof according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71 in combination with a physiologically acceptable carrier or excipient.

76. A pharmaceutical composition according to claim 75, wherein the composition is formulated as an injectible fluid, an aerosol, a cream, a gel, a pill, a capsule, a syrup or a transdermal patch.

77. A method for reducing calcium conductance of a cellular capsaicin receptor, comprising contacting a cell expressing a capsaicin receptor with at least one compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

each  $\equiv$  independently represents a single or double bond;

either: (a) A, B and E are independently  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N; or

(b) B is joined with A or E to form a fused 5- to 8-membered partially saturated ring that is substituted with from 0 to 3 substituents independently selected from  $\text{R}_1$ , and the other of A or E is  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N;

D and G are independently  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N;

W, X, Y and Z are independently  $\text{CR}_1$  or N;

T, U and V are independently  $\text{CR}_8$ ,  $\text{C}(\text{R}_8)_2$ , N or  $\text{NH}$ ;

$\text{R}_1$  is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

$\text{R}_3$  and  $\text{R}_4$  are:

(a) independently chosen from  $\text{R}_8$ ; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano,  $\text{C}_1$ - $\text{C}_6$ alkyl,  $\text{C}_1$ - $\text{C}_6$ haloalkyl,  $\text{C}_1$ - $\text{C}_6$ alkoxy,  $\text{C}_1$ - $\text{C}_6$ haloalkoxy,  $\text{C}_1$ - $\text{C}_6$ alkanoyl,  $\text{C}_2$ - $\text{C}_6$ alkyl ether, mono- and di- $(\text{C}_1$ - $\text{C}_6$ alkyl)amino,  $\text{C}_0$ - $\text{C}_4$ alkyl,  $-\text{N}(\text{H})\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl,  $-\text{N}(\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl) $_2$ , and  $-\text{N}(\text{C}_1$ - $\text{C}_6$ alkyl) $\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl;

$\text{R}_8$  is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro,  $\text{C}_1$ - $\text{C}_6$ alkyl,  $\text{C}_1$ - $\text{C}_6$ haloalkyl,  $\text{C}_1$ - $\text{C}_6$ alkoxy,  $\text{C}_1$ - $\text{C}_6$ haloalkoxy,  $\text{C}_1$ - $\text{C}_6$ alkanoyl,  $\text{C}_2$ - $\text{C}_6$ alkyl ether, mono- and di- $(\text{C}_1$ - $\text{C}_6$ alkyl)amino,  $-\text{N}(\text{H})\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl,  $-\text{N}(\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl) $_2$ ,  $-\text{N}(\text{C}_1$ - $\text{C}_6$ alkyl) $\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl, and 5 to 7 membered heteroalicyclic and heteroaryl rings;

L is independently chosen at each occurrence from a bond, O,  $\text{C}(=\text{O})$ ,  $\text{OC}(=\text{O})$ ,  $\text{C}(=\text{O})\text{O}$ ,  $\text{O}-\text{C}(=\text{O})\text{O}$ ,  $\text{S}(\text{O})_m$ ,  $\text{N}(\text{R}_x)$ ,  $\text{C}(=\text{O})\text{N}(\text{R}_x)$ ,  $\text{N}(\text{R}_x)\text{C}(=\text{O})$ ,  $\text{N}(\text{R}_x)\text{S}(\text{O})_m$ ,  $\text{S}(\text{O})_m\text{N}(\text{R}_x)$  and  $\text{N}[\text{S}(\text{O})_m\text{R}_x]\text{S}(\text{O})_m$ ; wherein m is independently selected at each occurrence from 0, 1 and 2; and  $\text{R}_x$  is independently selected at each occurrence from hydrogen and  $\text{C}_1$ - $\text{C}_8$ alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b)  $\text{C}_1$ - $\text{C}_8$ alkyl,  $\text{C}_2$ - $\text{C}_8$ alkenyl,  $\text{C}_2$ - $\text{C}_8$ alkynyl, mono- and di- $(\text{C}_1$ - $\text{C}_4$ alkyl)amino( $\text{C}_0$ - $\text{C}_4$ alkyl), phenyl $\text{C}_0$ - $\text{C}_4$ alkyl, (5-membered heteroaryl) $\text{C}_0$ - $\text{C}_4$ alkyl and (5- to 7-membered heterocycloalkyl) $\text{C}_0$ - $\text{C}_4$ alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo,  $\text{C}_1$ - $\text{C}_6$ alkyl,  $\text{C}_1$ - $\text{C}_6$ haloalkyl,  $\text{C}_1$ - $\text{C}_6$ alkoxy,  $\text{C}_1$ - $\text{C}_6$ haloalkoxy, aminocarbonyl, amino $\text{C}_1$ - $\text{C}_6$ alkyl and mono- and di- $(\text{C}_1$ - $\text{C}_6$ alkyl)amino;

and thereby reducing calcium conductance of the capsaicin receptor.

78. A method according to claim 77, wherein the compound is a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71.


79. A method according to claim 77, wherein the cell is a neuronal cell that is contacted *in vivo* in an animal.

80. A method according to claim 79, wherein during contact the compound is present within a body fluid of the animal.

81. A method according to claim 79, wherein the animal is a human.

82. A method according to claim 79, wherein the compound is administered orally.

83. A method for inhibiting binding of vanilloid ligand to a capsaicin receptor *in vitro*, the method comprising contacting capsaicin receptor with at least one compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

each  $\equiv$  independently represents a single or double bond;

either: (a) A, B and E are independently  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N; or

(b) B is joined with A or E to form a fused 5- to 8-membered partially saturated ring that is substituted with from 0 to 3 substituents independently selected from  $\text{R}_1$ , and the other of A or E is  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N;

D and G are independently  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N;

W, X, Y and Z are independently  $\text{CR}_1$  or N;

T, U and V are independently  $\text{CR}_8$ ,  $\text{C}(\text{R}_8)_2$ , N or  $\text{NH}$ ;

$\text{R}_1$  is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

$\text{R}_3$  and  $\text{R}_4$  are:

(a) independently chosen from  $\text{R}_8$ ; or



(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkanoyl, C<sub>2</sub>-C<sub>6</sub>alkyl ether, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino, C<sub>0</sub>-C<sub>4</sub>alkyl, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl)<sub>2</sub>, and -N(C<sub>1</sub>-C<sub>6</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl;

R<sub>8</sub> is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkanoyl, C<sub>2</sub>-C<sub>6</sub>alkyl ether, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl)<sub>2</sub>, -N(C<sub>1</sub>-C<sub>6</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, and 5 to 7 membered heteroalicyclic and heteroaryl rings;


L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, OC(=O), S(O)<sub>m</sub>, N(R<sub>x</sub>), C(=O)N(R<sub>x</sub>), N(R<sub>x</sub>)C(=O), N(R<sub>x</sub>)S(O)<sub>m</sub>, S(O)<sub>m</sub>N(R<sub>x</sub>) and N[S(O)<sub>m</sub>R<sub>x</sub>]S(O)<sub>m</sub>; wherein m is independently selected at each occurrence from 0, 1 and 2; and R<sub>x</sub> is independently selected at each occurrence from hydrogen and C<sub>1</sub>-C<sub>8</sub>alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b) C<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>2</sub>-C<sub>8</sub>alkenyl, C<sub>2</sub>-C<sub>8</sub>alkynyl, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino(C<sub>0</sub>-C<sub>4</sub>alkyl), phenylC<sub>0</sub>-C<sub>4</sub>alkyl, (5-membered heteroaryl)C<sub>0</sub>-C<sub>4</sub>alkyl and (5- to 7-membered heterocycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, aminocarbonyl, aminoC<sub>1</sub>-C<sub>6</sub>alkyl and mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino;

under conditions and in an amount sufficient to detectably inhibit vanilloid ligand binding to capsaicin receptor.

84. A method according to claim 83, wherein the compound is a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71.

85. A method for inhibiting binding of vanilloid ligand to capsaicin receptor in a patient, comprising contacting cells expressing capsaicin receptor in the patient with a compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

each  $\text{---}$  independently represents a single or double bond;

either: (a) A, B and E are independently  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N; or

(b) B is joined with A or E to form a fused 5- to 8-membered partially saturated ring that is substituted with from 0 to 3 substituents independently selected from  $\text{R}_1$ , and the other of A or E is  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N;

D and G are independently  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N;

W, X, Y and Z are independently  $\text{CR}_1$  or N;

T, U and V are independently  $\text{CR}_8$ ,  $\text{C}(\text{R}_8)_2$ , N or NH;

$\text{R}_1$  is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

$\text{R}_3$  and  $\text{R}_4$  are:

(a) independently chosen from  $\text{R}_8$ ; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano,  $\text{C}_1$ - $\text{C}_6$ alkyl,  $\text{C}_1$ - $\text{C}_6$ haloalkyl,  $\text{C}_1$ - $\text{C}_6$ alkoxy,  $\text{C}_1$ - $\text{C}_6$ haloalkoxy,  $\text{C}_1$ - $\text{C}_6$ alkanoyl,  $\text{C}_2$ - $\text{C}_6$ alkyl ether, mono- and di- $(\text{C}_1$ - $\text{C}_6$ alkyl)amino,  $\text{C}_0$ - $\text{C}_4$ alkyl,  $-\text{N}(\text{H})\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl,  $-\text{N}(\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl) $_2$ , and  $-\text{N}(\text{C}_1$ - $\text{C}_6$ alkyl) $\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl;

$\text{R}_8$  is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro,  $\text{C}_1$ - $\text{C}_6$ alkyl,  $\text{C}_1$ - $\text{C}_6$ haloalkyl,  $\text{C}_1$ - $\text{C}_6$ alkoxy,  $\text{C}_1$ - $\text{C}_6$ haloalkoxy,  $\text{C}_1$ - $\text{C}_6$ alkanoyl,  $\text{C}_2$ - $\text{C}_6$ alkyl ether, mono- and di- $(\text{C}_1$ - $\text{C}_6$ alkyl)amino,  $-\text{N}(\text{H})\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl,  $-\text{N}(\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl) $_2$ , and  $-\text{N}(\text{C}_1$ - $\text{C}_6$ alkyl) $\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl, and 5 to 7 membered heteroalicyclic and heteroaryl rings;

L is independently chosen at each occurrence from a bond, O,  $\text{C}(=\text{O})$ ,  $\text{OC}(=\text{O})$ ,  $\text{C}(=\text{O})\text{O}$ ,  $\text{O}-\text{C}(=\text{O})\text{O}$ ,  $\text{S}(\text{O})_m$ ,  $\text{N}(\text{R}_x)$ ,  $\text{C}(=\text{O})\text{N}(\text{R}_x)$ ,  $\text{N}(\text{R}_x)\text{C}(=\text{O})$ ,  $\text{N}(\text{R}_x)\text{S}(\text{O})_m$ ,  $\text{S}(\text{O})_m\text{N}(\text{R}_x)$  and  $\text{N}[\text{S}(\text{O})_m\text{R}_x]\text{S}(\text{O})_m$ ; wherein m is independently selected at each occurrence from 0, 1 and 2; and  $\text{R}_x$  is independently selected at each occurrence from hydrogen and  $\text{C}_1$ - $\text{C}_8$ alkyl; and


M is independently selected at each occurrence from (a) hydrogen; and (b)  $\text{C}_1$ - $\text{C}_8$ alkyl,  $\text{C}_2$ - $\text{C}_8$ alkenyl,  $\text{C}_2$ - $\text{C}_8$ alkynyl, mono- and di- $(\text{C}_1$ - $\text{C}_4$ alkyl)amino,  $(\text{C}_0$ - $\text{C}_4$ alkyl), phenyl,  $(\text{C}_0$ - $\text{C}_4$ alkyl), (5-membered heteroaryl),  $(\text{C}_0$ - $\text{C}_4$ alkyl) and (5- to 7-membered heterocycloalkyl),  $(\text{C}_0$ - $\text{C}_4$ alkyl), each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo,  $\text{C}_1$ - $\text{C}_6$ alkyl,  $\text{C}_1$ - $\text{C}_6$ haloalkyl,  $\text{C}_1$ - $\text{C}_6$ alkoxy,  $\text{C}_1$ - $\text{C}_6$ haloalkoxy, aminocarbonyl, amino,  $\text{C}_1$ - $\text{C}_6$ alkyl and mono- and di- $(\text{C}_1$ - $\text{C}_6$ alkyl)amino.

in an amount sufficient to detectably inhibit vanilloid ligand binding to cells expressing a cloned capsaicin receptor *in vitro*, and thereby inhibiting binding of vanilloid ligand to the capsaicin receptor in the patient.

86. A method according to claim 85, wherein the compound is a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71.

87. A method according to claim 85, wherein the patient is a human.

88. A method for treating a condition responsive to capsaicin receptor modulation in a patient, comprising administering to the patient a capsaicin receptor modulatory amount of at least one compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

each  $\equiv$  independently represents a single or double bond;

either: (a) A, B and E are independently  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N; or

(b) B is joined with A or E to form a fused 5- to 8-membered partially saturated ring that is substituted with from 0 to 3 substituents independently selected from  $\text{R}_1$ , and the other of A or E is  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N;

D and G are independently  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N;

W, X, Y and Z are independently  $\text{CR}_1$  or N;

T, U and V are independently  $\text{CR}_8$ ,  $\text{C}(\text{R}_8)_2$ , N or NH;

$\text{R}_1$  is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

$\text{R}_3$  and  $\text{R}_4$  are:

(a) independently chosen from  $\text{R}_8$ ; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano,  $\text{C}_1$ - $\text{C}_6$ alkyl,  $\text{C}_1$ - $\text{C}_6$ haloalkyl,  $\text{C}_1$ - $\text{C}_6$ alkoxy,  $\text{C}_1$ -


C<sub>6</sub>haloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkanoyl, C<sub>2</sub>-C<sub>6</sub>alkyl ether, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)aminoC<sub>0</sub>-C<sub>4</sub>alkyl, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl)<sub>2</sub>, and -N(C<sub>1</sub>-C<sub>6</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl;  
R<sub>8</sub> is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkanoyl, C<sub>2</sub>-C<sub>6</sub>alkyl ether, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl)<sub>2</sub>, -N(C<sub>1</sub>-C<sub>6</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, and 5 to 7 membered heteroalicyclic and heteroaryl rings;  
L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, S(O)<sub>m</sub>, N(R<sub>x</sub>), C(=O)N(R<sub>x</sub>), N(R<sub>x</sub>)C(=O), N(R<sub>x</sub>)S(O)<sub>m</sub>, S(O)<sub>m</sub>N(R<sub>x</sub>) and N[S(O)<sub>m</sub>R<sub>x</sub>]S(O)<sub>m</sub>; wherein m is independently selected at each occurrence from 0, 1 and 2; and R<sub>x</sub> is independently selected at each occurrence from hydrogen and C<sub>1</sub>-C<sub>8</sub>alkyl; and  
M is independently selected at each occurrence from (a) hydrogen; and (b) C<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>2</sub>-C<sub>8</sub>alkenyl, C<sub>2</sub>-C<sub>8</sub>alkynyl, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino(C<sub>0</sub>-C<sub>4</sub>alkyl), phenylC<sub>0</sub>-C<sub>4</sub>alkyl, (5-membered heteroaryl)C<sub>0</sub>-C<sub>4</sub>alkyl and (5- to 7-membered heterocycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, aminocarbonyl, aminoC<sub>1</sub>-C<sub>6</sub>alkyl and mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino.  
and thereby alleviating the condition in the patient.

89. A method according to claim 88, wherein the compound is a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71.

90. A method according to claim 88, wherein the patient is suffering from (i) exposure to capsaicin, (ii) burn or irritation due to exposure to heat, (iii) burns or irritation due to exposure to light, (iv) burn, bronchoconstriction or irritation due to exposure to tear gas, air pollutants or pepper spray, or (v) burn or irritation due to exposure to acid.

91. A method according to claim 88, wherein the condition is treating asthma or chronic obstructive pulmonary disease.

92. A method for treating pain in a patient, comprising administering to a patient suffering from pain a capsaicin receptor modulatory amount of at least one compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

each  $\text{---}$  independently represents a single or double bond;

either: (a) A, B and E are independently  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N; or

(b) B is joined with A or E to form a fused 5- to 8-membered partially saturated ring that is substituted with from 0 to 3 substituents independently selected from  $\text{R}_1$ , and the other of A or E is  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N;

D and G are independently  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N;

W, X, Y and Z are independently  $\text{CR}_1$  or N;

T, U and V are independently  $\text{CR}_8$ ,  $\text{C}(\text{R}_8)_2$ , N or  $\text{NH}$ ;

$\text{R}_1$  is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

$\text{R}_3$  and  $\text{R}_4$  are:

(a) independently chosen from  $\text{R}_8$ ; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano,  $\text{C}_1$ - $\text{C}_6$ alkyl,  $\text{C}_1$ - $\text{C}_6$ haloalkyl,  $\text{C}_1$ - $\text{C}_6$ alkoxy,  $\text{C}_1$ - $\text{C}_6$ haloalkoxy,  $\text{C}_1$ - $\text{C}_6$ alkanoyl,  $\text{C}_2$ - $\text{C}_6$ alkyl ether, mono- and di- $(\text{C}_1$ - $\text{C}_6$ alkyl)amino,  $\text{C}_0$ - $\text{C}_4$ alkyl,  $-\text{N}(\text{H})\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl,  $-\text{N}(\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl) $_2$ , and  $-\text{N}(\text{C}_1$ - $\text{C}_6$ alkyl) $\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl;

$\text{R}_8$  is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro,  $\text{C}_1$ - $\text{C}_6$ alkyl,  $\text{C}_1$ - $\text{C}_6$ haloalkyl,  $\text{C}_1$ - $\text{C}_6$ alkoxy,  $\text{C}_1$ - $\text{C}_6$ haloalkoxy,  $\text{C}_1$ - $\text{C}_6$ alkanoyl,  $\text{C}_2$ - $\text{C}_6$ alkyl ether, mono- and di- $(\text{C}_1$ - $\text{C}_6$ alkyl)amino,  $-\text{N}(\text{H})\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl,  $-\text{N}(\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl) $_2$ ,  $-\text{N}(\text{C}_1$ - $\text{C}_6$ alkyl) $\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl, and 5 to 7 membered heteroalicyclic and heteroaryl rings;

L is independently chosen at each occurrence from a bond, O,  $\text{C}(=\text{O})$ ,  $\text{OC}(=\text{O})$ ,  $\text{C}(=\text{O})\text{O}$ ,  $\text{O}-\text{C}(=\text{O})\text{O}$ ,  $\text{S}(\text{O})_m$ ,  $\text{N}(\text{R}_x)$ ,  $\text{C}(=\text{O})\text{N}(\text{R}_x)$ ,  $\text{N}(\text{R}_x)\text{C}(=\text{O})$ ,  $\text{N}(\text{R}_x)\text{S}(\text{O})_m$ ,  $\text{S}(\text{O})_m\text{N}(\text{R}_x)$  and  $\text{N}[\text{S}(\text{O})_m\text{R}_x]\text{S}(\text{O})_m$ ; wherein m is independently selected at each occurrence from 0, 1 and 2; and  $\text{R}_x$  is independently selected at each occurrence from hydrogen and  $\text{C}_1$ - $\text{C}_8$ alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b) C<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>2</sub>-C<sub>8</sub>alkenyl, C<sub>2</sub>-C<sub>8</sub>alkynyl, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino(C<sub>0</sub>-C<sub>4</sub>alkyl), phenylC<sub>0</sub>-C<sub>4</sub>alkyl, (5-membered heteroaryl)C<sub>0</sub>-C<sub>4</sub>alkyl and (5- to 7-membered heterocycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, aminocarbonyl, aminoC<sub>1</sub>-C<sub>6</sub>alkyl and mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino. and thereby alleviating pain in the patient.

93. A method according to claim 92, wherein the compound is a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71.


94. A method according to claim 92, wherein the patient is suffering from neuropathic pain.

95. A method according to claim 92, wherein the patient is suffering from mechanical pain.

96. A method according to claim 92, wherein the pain is associated with a condition selected from: postmastectomy pain syndrome, stump pain, phantom limb pain, oral neuropathic pain, toothache, postherpetic neuralgia, diabetic neuropathy, reflex sympathetic dystrophy, trigeminal neuralgia, osteoarthritis, rheumatoid arthritis, fibromyalgia, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, bilateral peripheral neuropathy, causalgia, neuritis, neuronitis, neuralgia, AIDS-related neuropathy, MS-related neuropathy, spinal cord injury-related pain, surgery-related pain, musculoskeletal pain, back pain, headache, migraine, angina, labor, hemorrhoids, dyspepsia, Charcot's pains, intestinal gas, menstruation, cancer, venom exposure, irritable bowel syndrome, inflammatory bowel disease, and/or trauma.

97. A method according to claim 92, wherein the patient is a human.

98. A method for treating itch in a patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

each  $\equiv$  independently represents a single or double bond;

either: (a) A, B and E are independently  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N; or

(b) B is joined with A or E to form a fused 5- to 8-membered partially saturated ring that is substituted with from 0 to 3 substituents independently selected from  $\text{R}_1$ , and the other of A or E is  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N;

D and G are independently  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N;

W, X, Y and Z are independently  $\text{CR}_1$  or N;

T, U and V are independently  $\text{CR}_8$ ,  $\text{C}(\text{R}_8)_2$ , N or NH;

$\text{R}_1$  is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

$\text{R}_3$  and  $\text{R}_4$  are:

(a) independently chosen from  $\text{R}_8$ ; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano,  $\text{C}_1$ - $\text{C}_6$ alkyl,  $\text{C}_1$ - $\text{C}_6$ haloalkyl,  $\text{C}_1$ - $\text{C}_6$ alkoxy,  $\text{C}_1$ - $\text{C}_6$ haloalkoxy,  $\text{C}_1$ - $\text{C}_6$ alkanoyl,  $\text{C}_2$ - $\text{C}_6$ alkyl ether, mono- and di- $(\text{C}_1$ - $\text{C}_6$ alkyl)amino,  $\text{C}_0$ - $\text{C}_4$ alkyl,  $-\text{N}(\text{H})\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl,  $-\text{N}(\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl) $_2$ , and  $-\text{N}(\text{C}_1$ - $\text{C}_6$ alkyl) $\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl;


$\text{R}_8$  is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro,  $\text{C}_1$ - $\text{C}_6$ alkyl,  $\text{C}_1$ - $\text{C}_6$ haloalkyl,  $\text{C}_1$ - $\text{C}_6$ alkoxy,  $\text{C}_1$ - $\text{C}_6$ haloalkoxy,  $\text{C}_1$ - $\text{C}_6$ alkanoyl,  $\text{C}_2$ - $\text{C}_6$ alkyl ether, mono- and di- $(\text{C}_1$ - $\text{C}_6$ alkyl)amino,  $-\text{N}(\text{H})\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl,  $-\text{N}(\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl) $_2$ ,  $-\text{N}(\text{C}_1$ - $\text{C}_6$ alkyl) $\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl, and 5 to 7 membered heteroalicyclic and heteroaryl rings;

L is independently chosen at each occurrence from a bond, O,  $\text{C}(=\text{O})$ ,  $\text{OC}(=\text{O})$ ,  $\text{C}(=\text{O})\text{O}$ ,  $\text{O}-\text{C}(=\text{O})\text{O}$ ,  $\text{S}(\text{O})_m$ ,  $\text{N}(\text{R}_x)$ ,  $\text{C}(=\text{O})\text{N}(\text{R}_x)$ ,  $\text{N}(\text{R}_x)\text{C}(=\text{O})$ ,  $\text{N}(\text{R}_x)\text{S}(\text{O})_m$ ,  $\text{S}(\text{O})_m\text{N}(\text{R}_x)$  and

$N[S(O)_mR_x]S(O)_m$ ; wherein  $m$  is independently selected at each occurrence from 0, 1 and 2; and  $R_x$  is independently selected at each occurrence from hydrogen and  $C_1$ - $C_8$ alkyl; and  $M$  is independently selected at each occurrence from (a) hydrogen; and (b)  $C_1$ - $C_8$ alkyl,  $C_2$ - $C_8$ alkenyl,  $C_2$ - $C_8$ alkynyl, mono- and di- $(C_1$ - $C_4$ alkyl)amino( $C_0$ - $C_4$ alkyl), phenyl $C_0$ - $C_4$ alkyl, (5-membered heteroaryl) $C_0$ - $C_4$ alkyl and (5- to 7-membered heterocycloalkyl) $C_0$ - $C_4$ alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo,  $C_1$ - $C_6$ alkyl,  $C_1$ - $C_6$ haloalkyl,  $C_1$ - $C_6$ alkoxy,  $C_1$ - $C_6$ haloalkoxy, aminocarbonyl, amino $C_1$ - $C_6$ alkyl and mono- and di- $(C_1$ - $C_6$ alkyl)amino. and thereby alleviating itch in the patient.

99. A method according to claim 98, wherein the compound is a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71.

100. A method for treating cough or hiccup in a patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

each --- independently represents a single or double bond;

either: (a) A, B and E are independently  $CR_1$ ,  $C(R_1)_2$ ,  $NR_1$  or N; or

(b) B is joined with A or E to form a fused 5- to 8-membered partially saturated ring that is substituted with from 0 to 3 substituents independently selected from  $R_1$ , and the other of A or E is  $CR_1$ ,  $C(R_1)_2$ ,  $NR_1$  or N;

D and G are independently  $CR_1$ ,  $C(R_1)_2$ ,  $NR_1$  or N;

W, X, Y and Z are independently  $CR_1$  or N;

T, U and V are independently  $CR_8$ ,  $C(R_8)_2$ , N or  $NH$ ;

$R_1$  is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

$R_3$  and  $R_4$  are:

(a) independently chosen from  $R_8$ ; or



(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkanoyl, C<sub>2</sub>-C<sub>6</sub>alkyl ether, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino, C<sub>0</sub>-C<sub>4</sub>alkyl, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl)<sub>2</sub>, and -N(C<sub>1</sub>-C<sub>6</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl;

R<sub>8</sub> is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkanoyl, C<sub>2</sub>-C<sub>6</sub>alkyl ether, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl)<sub>2</sub> and -N(C<sub>1</sub>-C<sub>6</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, and 5 to 7 membered heteroalicyclic and heteroaryl rings;


L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, S(O)<sub>m</sub>, N(R<sub>x</sub>), C(=O)N(R<sub>x</sub>), N(R<sub>x</sub>)C(=O), N(R<sub>x</sub>)S(O)<sub>m</sub>, S(O)<sub>m</sub>N(R<sub>x</sub>) and N[S(O)<sub>m</sub>R<sub>x</sub>]S(O)<sub>m</sub>; wherein m is independently selected at each occurrence from 0, 1 and 2; and R<sub>x</sub> is independently selected at each occurrence from hydrogen and C<sub>1</sub>-C<sub>8</sub>alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b) C<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>2</sub>-C<sub>8</sub>alkenyl, C<sub>2</sub>-C<sub>8</sub>alkynyl, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino(C<sub>0</sub>-C<sub>4</sub>alkyl), phenylC<sub>0</sub>-C<sub>4</sub>alkyl, (5-membered heteroaryl)C<sub>0</sub>-C<sub>4</sub>alkyl and (5- to 7-membered heterocycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, aminocarbonyl, aminoC<sub>1</sub>-C<sub>6</sub>alkyl and mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino.

and thereby alleviating cough or hiccup in the patient.

101. A method according to claim 100, wherein the compound is a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71.

102. A method for treating urinary incontinence in a patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

each  $\equiv$  independently represents a single or double bond;

either: (a) A, B and E are independently  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N; or

(b) B is joined with A or E to form a fused 5- to 8-membered partially saturated ring that is substituted with from 0 to 3 substituents independently selected from  $\text{R}_1$ , and the other of A or E is  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N;

D and G are independently  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N;

W, X, Y and Z are independently  $\text{CR}_1$  or N;

T, U and V are independently  $\text{CR}_8$ ,  $\text{C}(\text{R}_8)_2$ , N or NH;

$\text{R}_1$  is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

$\text{R}_3$  and  $\text{R}_4$  are:

(a) independently chosen from  $\text{R}_8$ ; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano,  $\text{C}_1$ - $\text{C}_6$ alkyl,  $\text{C}_1$ - $\text{C}_6$ haloalkyl,  $\text{C}_1$ - $\text{C}_6$ alkoxy,  $\text{C}_1$ - $\text{C}_6$ haloalkoxy,  $\text{C}_1$ - $\text{C}_6$ alkanoyl,  $\text{C}_2$ - $\text{C}_6$ alkyl ether, mono- and di- $(\text{C}_1$ - $\text{C}_6$ alkyl)amino,  $\text{C}_0$ - $\text{C}_4$ alkyl,  $-\text{N}(\text{H})\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl,  $-\text{N}(\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl) $_2$ , and  $-\text{N}(\text{C}_1$ - $\text{C}_6$ alkyl) $\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl;

$\text{R}_8$  is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro,  $\text{C}_1$ - $\text{C}_6$ alkyl,  $\text{C}_1$ - $\text{C}_6$ haloalkyl,  $\text{C}_1$ - $\text{C}_6$ alkoxy,  $\text{C}_1$ - $\text{C}_6$ haloalkoxy,  $\text{C}_1$ - $\text{C}_6$ alkanoyl,  $\text{C}_2$ - $\text{C}_6$ alkyl ether, mono- and di- $(\text{C}_1$ - $\text{C}_6$ alkyl)amino,  $-\text{N}(\text{H})\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl,  $-\text{N}(\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl) $_2$ ,  $-\text{N}(\text{C}_1$ - $\text{C}_6$ alkyl) $\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl, and 5 to 7 membered heteroalicyclic and heteroaryl rings;


L is independently chosen at each occurrence from a bond, O,  $\text{C}(=\text{O})$ ,  $\text{OC}(=\text{O})$ ,  $\text{C}(=\text{O})\text{O}$ ,  $\text{O}-\text{C}(=\text{O})\text{O}$ ,  $\text{S}(\text{O})_m$ ,  $\text{N}(\text{R}_x)$ ,  $\text{C}(=\text{O})\text{N}(\text{R}_x)$ ,  $\text{N}(\text{R}_x)\text{C}(=\text{O})$ ,  $\text{N}(\text{R}_x)\text{S}(\text{O})_m$ ,  $\text{S}(\text{O})_m\text{N}(\text{R}_x)$  and  $\text{N}[\text{S}(\text{O})_m\text{R}_x]\text{S}(\text{O})_m$ ; wherein m is independently selected at each occurrence from 0, 1 and 2; and  $\text{R}_x$  is independently selected at each occurrence from hydrogen and  $\text{C}_1$ - $\text{C}_8$ alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b)  $\text{C}_1$ - $\text{C}_8$ alkyl,  $\text{C}_2$ - $\text{C}_8$ alkenyl,  $\text{C}_2$ - $\text{C}_8$ alkynyl, mono- and di- $(\text{C}_1$ - $\text{C}_4$ alkyl)amino,  $(\text{C}_0$ - $\text{C}_4$ alkyl), phenyl,  $(\text{C}_0$ - $\text{C}_4$ alkyl), (5-membered heteroaryl),  $(\text{C}_0$ - $\text{C}_4$ alkyl) and (5- to 7-membered heterocycloalkyl),  $(\text{C}_0$ - $\text{C}_4$ alkyl), each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo,  $\text{C}_1$ - $\text{C}_6$ alkyl,  $\text{C}_1$ - $\text{C}_6$ haloalkyl,  $\text{C}_1$ - $\text{C}_6$ alkoxy,  $\text{C}_1$ - $\text{C}_6$ haloalkoxy, aminocarbonyl, amino,  $\text{C}_1$ - $\text{C}_6$ alkyl and mono- and di- $(\text{C}_1$ - $\text{C}_6$ alkyl)amino;

and thereby alleviating urinary incontinence in the patient.

103. A method according to claim 102, wherein the compound is a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71.

104. A method for promoting weight loss in an obese patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

each  $\text{---}$  independently represents a single or double bond;

either: (a) A, B and E are independently  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N; or

(b) B is joined with A or E to form a fused 5- to 8-membered partially saturated ring that is substituted with from 0 to 3 substituents independently selected from  $\text{R}_1$ , and the other of A or E is  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N;

D and G are independently  $\text{CR}_1$ ,  $\text{C}(\text{R}_1)_2$ ,  $\text{NR}_1$  or N;

W, X, Y and Z are independently  $\text{CR}_1$  or N;

T, U and V are independently  $\text{CR}_8$ ,  $\text{C}(\text{R}_8)_2$ , N or  $\text{NH}$ ;

$\text{R}_1$  is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

$\text{R}_3$  and  $\text{R}_4$  are:

(a) independently chosen from  $\text{R}_8$ ; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano,  $\text{C}_1$ - $\text{C}_6$ alkyl,  $\text{C}_1$ - $\text{C}_6$ haloalkyl,  $\text{C}_1$ - $\text{C}_6$ alkoxy,  $\text{C}_1$ - $\text{C}_6$ haloalkoxy,  $\text{C}_1$ - $\text{C}_6$ alkanoyl,  $\text{C}_2$ - $\text{C}_6$ alkyl ether, mono- and di- $(\text{C}_1$ - $\text{C}_6$ alkyl)amino,  $\text{C}_0$ - $\text{C}_4$ alkyl,  $-\text{N}(\text{H})\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl,  $-\text{N}(\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl) $_2$ , and  $-\text{N}(\text{C}_1$ - $\text{C}_6$ alkyl) $\text{SO}_2\text{C}_1$ - $\text{C}_6$ alkyl;

$\text{R}_8$  is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro,  $\text{C}_1$ - $\text{C}_6$ alkyl,  $\text{C}_1$ - $\text{C}_6$ haloalkyl,  $\text{C}_1$ - $\text{C}_6$ alkoxy,  $\text{C}_1$ - $\text{C}_6$ haloalkoxy,  $\text{C}_1$ - $\text{C}_6$ alkanoyl,  $\text{C}_2$ -

C<sub>6</sub>alkyl ether, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino, -N(H)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, -N(SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl)<sub>2</sub>, -N(C<sub>1</sub>-C<sub>6</sub>alkyl)SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, and 5 to 7 membered heteroalicyclic and heteroaryl rings;  
 L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, S(O)<sub>m</sub>, N(R<sub>x</sub>), C(=O)N(R<sub>x</sub>), N(R<sub>x</sub>)C(=O), N(R<sub>x</sub>)S(O)<sub>m</sub>, S(O)<sub>m</sub>N(R<sub>x</sub>) and N[S(O)<sub>m</sub>R<sub>x</sub>]S(O)<sub>m</sub>; wherein m is independently selected at each occurrence from 0, 1 and 2; and R<sub>x</sub> is independently selected at each occurrence from hydrogen and C<sub>1</sub>-C<sub>8</sub>alkyl; and  
 M is independently selected at each occurrence from (a) hydrogen; and (b) C<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>2</sub>-C<sub>8</sub>alkenyl, C<sub>2</sub>-C<sub>8</sub>alkynyl, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino(C<sub>0</sub>-C<sub>4</sub>alkyl), phenylC<sub>0</sub>-C<sub>4</sub>alkyl, (5-membered heteroaryl)C<sub>0</sub>-C<sub>4</sub>alkyl and (5- to 7-membered heterocycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, aminocarbonyl, aminoC<sub>1</sub>-C<sub>6</sub>alkyl and mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino; and thereby promoting weight loss in the patient.

105. A method according to claim 104, wherein the compound is a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71.

106. A compound or pharmaceutically acceptable form thereof according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71, wherein the compound or pharmaceutically acceptable form thereof is radiolabeled.

107. A method for determining the presence or absence of capsaicin receptor in a sample, comprising the steps of:

- (a) contacting a sample with a compound or pharmaceutically acceptable form thereof according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71 under conditions that permit binding of the compound to capsaicin receptor; and
- (b) detecting a level of the compound bound to capsaicin receptor, and therefrom determining the presence or absence of capsaicin receptor in the sample.

108. A method according to claim 107, wherein the compound is a radiolabeled compound according to claim 106, and wherein the step of detection comprises the steps of:

- (i) separating unbound compound from bound compound; and
- (ii) detecting the presence or absence of bound compound in the sample.

109. A packaged pharmaceutical preparation, comprising:
- (a) a pharmaceutical composition according to claim 75 in a container; and
  - (b) instructions for using the composition to treat pain.

110. A packaged pharmaceutical preparation, comprising:
- (a) a pharmaceutical composition according to claim 75 in a container; and
  - (b) instructions for using the composition to treat cough or hiccup.

111. A packaged pharmaceutical preparation, comprising:
- (a) a pharmaceutical composition according to claim 75 in a container; and
  - (b) instructions for using the composition to treat urinary incontinence.

112. A packaged pharmaceutical preparation, comprising:
- (a) a pharmaceutical composition according to claim 75 in a container; and
  - (b) instructions for using the composition to treat obesity.

113. Use of a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71 as a medicament for the treatment of a patient suffering from a condition responsive to capsaicin receptor modulation.

114. Use of a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71 as a medicament for the treatment of a patient suffering from a condition responsive to capsaicin receptor modulation selected from (i) exposure to capsaicin, (ii) burn or irritation due to exposure to heat, (iii) burns or irritation due to exposure to light, (iv) burn, bronchoconstriction or irritation due to exposure to tear gas, air pollutants or pepper spray, or (v) burn or irritation due to exposure to acid.

115. Use of a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71 as a medicament for the treatment of a patient suffering from to pain.

116. Use of a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71 as a medicament for the treatment of a patient suffering from neuropathic pain associated with a condition selected from: postmastectomy pain syndrome, stump pain, phantom limb pain, oral neuropathic pain, toothache, postherpetic neuralgia, diabetic neuropathy, reflex sympathetic

dystrophy, trigeminal neuralgia, osteoarthritis, rheumatoid arthritis, fibromyalgia, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, bilateral peripheral neuropathy, causalgia, neuritis, neuronitis, neuralgia, AIDS-related neuropathy, MS-related neuropathy, spinal cord injury-related pain, surgery-related pain, musculoskeletal pain, back pain, headache, migraine, angina, labor, hemorrhoids, dyspepsia, Charcot's pains, intestinal gas, menstruation, cancer, venom exposure, irritable bowel syndrome, inflammatory bowel disease and trauma.

117. Use of a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71 as a medicament for the treatment of a patient suffering from or susceptible to an itch.

118. Use of a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71 as a medicament for the treatment of a patient suffering from or susceptible to urinary incontinence.

119. Use of a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71 as a medicament for promoting weight loss in an obese patient.